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ABSTRACT 
While acknowledging the importance of microenvironment-related events, e.g. Helicobacter 
pylori (H. pylori) infection and atrophy, occurring during the gastric cancer (GC) progression, 
at present we have inadequate data to say to what extent these conditions could affect the 
further development of GC and what we should do for patients with these changes. In this 
thesis, with different focuses for each project, we aim to confirm the observed increasing 
trend of atrophic corpus gastritis (ACG) among young middle-age Swedes, to detect true 
carcinogenic H. pylori strains, and to quantify excess GC risks among endoscopy or 
appendectomized patients. With all the data obtained from our projects, a more accurate risk 
stratification for patients with potential probability of GC development would be a reality.  
In Study I, based on Northern Sweden MONICA quinquennial population-based cross-
sectional surveys conducted between 1990-2009, we randomly drew 5284 serum samples 
from all participants aged 35-64. Serologically defined ACG was determined by testing 
serum level of pepsinogen I (PG-I). The results revealed a surprising monotonic and 
significant upward trend in prevalence of PG-I-defined ACG (from 22 to 64 per 1000) in the 
youngest investigated age bracket 35-44 years. While in the oldest investigated age band (54-
65 years), there was a clear and expected decline. Our further exploration, through the cross-
sectional case-control analysis, indicated that CagA seropositivity was the strongest predictor 
of ACG presence (odds ratio [OR] =2.29). Further significant risk factors included diabetes, 
low education level and high body mass index (BMI). Interaction analyses indicated that the 
association between BMI and ACG was confined to the age category 35-44 years, where 
overweight and obesity, respectively, were linked to 2.8-fold and 4.7-fold increased odds of 
having ACG. 
In Study II, a population-based case-control study, we measured antibodies against 17 H. 
pylori proteins using multiplex serology in sera from 268 cases and 222 frequency-matched 
controls. Unconditional multivariate logistic regression model was used for data analysis. In 
total, 15 proteins were significantly associated with increased GC risks, with the top three 
being CagA (OR=9.2), GroEL (6.6), HyuA (3.6). The excess risks were confined to non-
cardia GC, but did not differ significantly between intestinal and diffuse subtypes. Using 
principal component analysis, we identified two significant factors among individuals 
without advanced chronic atrophic gastritis (AG): a CagA-dominant factor (antibodies 
against CagA, VacA, Omp as prominent markers), and a non-CagA factor (antibodies against 
NapA and Catalase as prominent markers). Strong dose-response relationships with non-
cardia GC risks emerged for both antigen constellations: adjusted ORs (highest vs. lowest 
quartile) were 16.2 for the CagA-dominant factor, and 5.3 for the non-CagA factor. 
In Study III, based on a nationwide cohort consisting of all patients (n=405,211) with gastric 
biopsies on non-malignant indications between 1979 and 2011 in Sweden, we quantified that 
crude annual incidence rates of GC were 20×10
-5
 for the normal group, 42×10
-5
 for those with 
minor changes, 59×10
-5
 for the gastritis group, 100×10
-5
 for the AG group, 129×10
-5
 for the 
intestinal metaplasia (IM) group, and 263×10
-5
 for those with dysplasia. Compared to 
matching general Swedish population, the corresponding standardized incidence ratio (SIR) 
for overall GC was 1.0, 1.5, 1.8, 2.8, 3.4, and 6.5, respectively. The elevated GC incidence 
among precursor patients was stable throughout the follow-up period, and analysis restricted 
to the subset of participants with more than one biopsy suggested that the observed changes 
during re-evaluation(s) indeed have prognostic implications.   
Similarly, in Study IV, we estimated the relative risks of GC among appendectomized 
patients in another nationwide register-based cohort study, using Swedish general population 
as reference. In total, 480,382 eligible patients received appendectomy were followed during 
the period of 1970-2009 for GC occurrence. The results indicated that no excess GC risk 
(SIR=1.00, 95% CI 0.93-1.07) was noted after appendectomy. 
In conclusion, this thesis emphasizes that there is emerging evidence showing that GC, a 
fatal disease placing heavy burden on human health, might continue to be prevalent in the 
future. Given the large proportion of population affected by various stages of precancerous 
lesions, more accurate risk stratification is needed for optimizing the clinical management 
of these patients. H. pylori multiplex serology might be a useful tool for improving the 
overall cancer prediction capability. For patients biopsied on clinical indications, cost-
effective endoscopy surveillance program needs to be developed for those with proven 
high-risk mucosal lesions (AG/IM/dysplasia).   
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1 INTRODUCTION 
It has been established that the occurrence of gastric cancer (GC), typically the intestinal type 
of non-cardia GC
1
,  develops through a series of well-recognized events (inflammation-
metaplasia-dysplasia-carcinoma sequence, see Figure 1). This procedure, well known as 
Correa’s cascade2, 3, generally refers to a progression arising from normal mucosa, through 
chronic non-atrophic gastritis, atrophic gastritis (AG), intestinal metaplasia (IM), dysplasia, to 
ultimately GC. Despite declining incidence rates of GC have been documented in many 
developed countries, including Sweden, with disquieting reports indicating increasing 
presence of AG
4
 and incidence of non-cardia GC
5
 among young middle-age population, the 
changing tendency of GC incidence in the future is actually undetermined. 
H. pylori infection is the most recognized risk factor for GC and its precursors, by triggering 
the evolving precancerous cascade. However, its etiological role on carcinogenesis is far from 
clear, especially considering that H. pylori is unlikely to continually survive or colonize in a 
typically hypochlorhydric environment of AG. This grants plausibility to the notion that H. 
pylori may create an environment for intestinal-type gastric carcinogenesis (atrophy and 
hypochlorhydria) rather than causing the cancer directly. In contrast, based on the preliminary 
studies on stomach microbial ecology in cancer patients, it is reasonable to postulate that 
other microenvironment- related factors might be involved in the development of GC. 
Moreover, although the development of GC has been widely investigated and its underlying 
mechanisms are partly uncovered, in practice, the management of these pre-cancer events is 
still poor. A crucial reason is that, these earlier stages of the pathological changes commonly 
happen in a large proportion of the population, while an effective treatment for the later 
stages currently doesn’t exist. Therefore, accurate risk assessments for patients at various 
stages can be of great public health importance.  
This thesis focused on exploring the secular trend of AG in Sweden, detecting true 
carcinogenic H. pylori strains, and quantifying excess GC risks among endoscopy or 
appendectomized patients. We hope our findings could in turn help identify a subpopulation 
at extremely increased risk of GC, facilitating cost-effective and safe primary/secondary 
prevention for this deadly malignancy.    
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Figure 1. Changes of stomach microenvironment and gastric cancer carcinogenesis. Study focuses were marked 
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2 BACKGROUND 
2.1 GASTRIC CANCER 
2.1.1 Descriptive epidemiology 
Despite the declining incidence rates in many developed countries, GC still ranks amongst 
the most common cancers in the world (the most common neoplasm in the first estimate of 
global cancer incidence in 1975, and the 5
th
 in 2012)
6
. Also, this deadly malignancy 
contributes significantly to the overall mortality and accounted for 723,000 deaths (8.8% of 
the total) in 2012
6
, which made it the third leading cause of cancer-related death for both 
sexes worldwide. The epidemiology of GC is characterized by its prominent geographic 
variation and male dominance, with age-standardized incidence rates ranging from 3.3 in 
western Africa to 35.4 in eastern Asia for men, and from 2.6 in western Africa to 13.8 in 
eastern Asia for women
6
. 
In Sweden, the downward trend of GC can be dated back to 1940. However, in recent years, 
the fall appears to have slowed down in both genders (Figure 2). While the annual reduction 
during 1992-2001 was 4.4% and 3.9% among Swedish men and women, respectively
7
, it was 
2.1% and 1.0% during 2002-2011
8
. In addition, besides an upward incidence trend for non-
cardia GC which was recently reported among young US whites aged 25-39 years
5
, our 
previous study observed a possible increasing trend of AG among 35-44 years adults in 
Sweden
4
. All of the emerging evidence suggests that the changing pattern of this malignancy 
in the future is uncertain. 
 
Figure 2
*
. Age-standardized incidence rates of gastric cancer in Sweden, stratified by gender (according to the 
population of Europe) 
*
This figure was generated by online tool provided by The National Board of Health and Welfare 
(Socialstyrelsen) in Sweden (http://www.socialstyrelsen.se/statistik/statistikdatabas/cancer) 
 4 
2.1.2 Subtypes of gastric cancer 
More than 95% of all GC cases are diagnosed as adenocarcinoma
9
, indicating that the cancer 
originates from glandular epithelium of the stomach mucosa. Since GCs are overwhelmingly 
gastric adenocarcinomas (GAC), GAC is the main focus of this thesis. Other cancer types that 
can be found in the stomach include lymphoma, leiomycosarcoma, and neuroendocrine 
tumors. 
2.1.2.1 Cardia and non-cardia gastric cancer 
Anatomically, GC can be divided into cardia and non-cardia with respect to gastric subsite. 
Although this classification has been widely used in clinical/epidemiological studies, there is 
however no worldwide consensus on how to define this diagnostic category
10, 11
. In our 
studies, we applied a relatively conservative definition for cardia GC—tumor with its center 
located within 1 cm proximal and 2 cm distal to the gastroesophageal junction; while the 
others (those arising in fundus, body, antrum or pylorus of stomach, see Figure 3) were 
considered to be non-cardia (or distal) GCs
12
.   
 
Figure 3. Anatomy of the stomach 
Besides the distinction of origins, this classification may also indicate discrepancies in terms 
of epidemiology, etiology and prognosis. As opposed to the consistent finding of a declined 
incidence of non-cardia GC worldwide, the epidemiological evidence regarding the changing 
pattern of cardia GC incidence varied. A rising trend was shown in the US
11, 13
 and 
Singapore
14
, whereas investigations from other countries
12, 15, 16
 reported a constant incidence. 
In addition, although cardia GC is histologically identical to most of the distal GC 
(adenocarcinoma), the occurrence of these two subtypes of GC seems to respond to different 
environmental and genetic determinants
17, 18
. Clinically, cardia GC tends to be more 
aggressive
9
, thus with less favorable survival rate than that for non-cardia GC
19
. 
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2.1.2.2 Intestinal and diffuse types 
Two major histological subtypes of GAC, intestinal and diffuse, have been introduced by Dr. 
Laurén in 1965
1
 based on morphological differences. The tumor cells in intestinal-type 
tumors adhere to each other, and tend to arrange themselves in the formation of tubules or 
glands (well-differentiated). This is very similar to adenocarcinomas arising elsewhere in the 
intestinal tract, and hence designated as intestinal-type. In contrast, in diffuse-type 
carcinomas, a defect of intercellular adhesion molecules allows individual tumor cells to 
grow and invade neighboring structures without any regular formation (undifferentiated). 
With regard to the clinical characteristics, the intestinal type, usually having a long latent 
time, typically arises from a circumstance with precancerous lesions (e.g. IM or dysplasia), 
and prevails among the elderly; while the diffuse type is more likely to be with genetic 
abnormalities, and frequent in younger population. Although the former is thought to be more 
environment-related
20, 21
 than the latter, both subtypes have been associated with H. pylori 
infection
9
. Additionally, numerous studies have failed to find a prognostic difference, though 
some have suggested a survival advantage for patients with intestinal-type tumors
22
. 
2.2 STOMACH MICROENVIRONMENT 
2.2.1 Normal status of stomach microenvironment 
In a normal condition, the healthy stomach, acts as a reservoir where ingested food gets 
preliminarily digested by being contracted and mixed with gastric juice (the admixture of 
fluids that secreted into the stomach).    
The stomach, through gastric glands, secretes several factors which are necessary for 
maintaining its digestive functions. There are three types of glands located in different 
regions of the stomach. They can also be distinguished from each other by type of secretion
23
 
(Table 1).  
Table 1.  Different types of glands and their main secretions 
Gastric glands Location 
Principle epithelial 
secretory cells 
Secretion 
Cardiac glands Gastric cardia mucus-secreting cells Mucus 
Fundic (oxyntic) 
glands 
 
Fundus and body of stomach 
Parietal (oxyntic) cells Gastric acid (hydrochloric acid, HCI) 
and intrinsic factors 
Chief cells Pepsinogens (I and II) 
Mucous neck cells Mucus and pepsinogens (I and II) 
Pyloric glands Pylorus and antrum 
Mucous neck cells and 
mucus-secreting cells 
Mucus and pepsinogen II 
The layer of mucus, acting in concert with NaHCO3 which is secreted by surface mucous 
cells and serves as a neutralizing force, protects the stomach from the low PH and peptic 
conditions of the gastric lumen. This is known as the gastric mucosal barrier. 
Pepsinogens (PGs) are the inactive precursor zymogens of pepsin (the principle enzyme of 
gastric juice). There are two immunochemically distinct types of PG: PGI and PGII. PGI is 
secreted merely by the chief and mucous neck cells of the corpus, whereas PGII is also 
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produced by pyloric glands in the pylorus and antrum. Regardless of the heterogeneity of 
origin, both PGI and PGII can be converted rapidly to an enzymatically active form in a 
normally low pH environment created by the acidity of gastric juice. 
The secretion of HCI forms the typical acidic environment in the stomach. Although varied 
with the secretory rates, the normal human stomach (empty status) has a pH close to 2 
(ranging from approximately 1-3). In addition to providing a state optimizing the proteolytic 
activity of pepsin, the strong acidity kills nearly all ingested pathogens, yet offers a perfect 
condition for the lonely survival of H. pylori.  
2.2.2 Microenvironmental factors related to H. pylori infection 
2.2.2.1 H. pylori infection 
Pathology and changes in stomach microenvironment 
H. pylori is a spiral bacterium colonizing in the human stomach. It was first described in 
1874, and successfully cultured in 1982
24
. After colonization with H. pylori, essentially all 
infected persons develop chronic superficial gastritis, no matter whether or not there is any 
gastrointestinal symptoms. This inflammatory condition results in stimulation of gastrin 
release and impairment on structure and function of epithelial cells. The subsequent excess 
secretion of HCI (hyperchlorhydria) is a consequence of the elevated gastrin level. 
For the majority of the patients, induced inflammation is mainly restricted to the antrum, and 
this hyperchlorhydria status can persist, sometimes for the lifetime of the host, at a mild and  
harmless level; while for others, pangastritis (gastritis of both the corpus and antrum) 
gradually develops, which is a pattern of inflammation with the potential for progression 
along the Correa’s carcinogenic cascade25.  
Prevalence of H. pylori infection 
Approximately half of the world’s population has been infected by this microbe, rendering it 
one of the most common infections in humans
25
.  The geographic distribution of H. pylori 
infection is strongly associated with socioeconomic conditions. With the observed declines 
owing to improved sanitation in recent decades, the prevalence of H. pylori infection now is 
estimated to be 70% in developing countries and 30%–40% in the industrialized countries26. 
Predictive value for the occurrence of GC 
Although there is a consensus that the infection of H. pylori initiates the carcinogenic process 
in the stomach
25, 27
, since most infected patients end up in the subclinical phase or with minor 
subsequent tissue damage, it’s difficult to quantify the exactly causative role of H. pylori in 
the development of GC. The heterogeneity of infected H. pylori strains and host response 
have been proposed as the determinants for the discrepant pathogenic courses (i.e. gastritis, 
gastric ulcer, AG, etc.). Different strains could induce variations in complex immune 
response in human which might be reflected by specific antibody patterns. So far, antibody 
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against cytotoxin-associated antigen A (Cag A) is believed to be the most oncogenic 
biomarker of infection with high-risk H. pylori strain. However, the problem is that, the 
CagA-positive infection is also quite common — approximately 55%-89% even in a normal 
population
28
. With the development of multiplex serology, which will be capable of including 
CagA antigens from different strains (26695, G27, F32), the sero-positive rate of CagA could 
be even higher than in prior reports .This means that the existence of CagA alone provides 
gradually inadequate cues to predict the occurrence of GC. Further exploration on novel 
serum predictors is warranted. 
2.2.2.2 Atrophic corpus gastritis 
Pathology and changes in stomach microenvironment 
Atrophic corpus gastritis (ACG), also referred as advanced AG, is mainly the consequence of 
persistent H. pylori infection, which pathologically suggests the presence of chronic 
inflammatory cells and the disappearance of normal glands. Consequently to the continuous 
loss of oxyntic glands and the replacement by intestinal glands, the gastric acid secretion 
decreases steeply; and by then the hypochlorhydric condition is established in atrophic 
mucosa, creating an environment allowing survival of other microbes, in parallel with a 
notable decline in density of H. pylori.  
The onset of atrophy is of particular importance because it is well recognized as a risk factor 
for GC
29
. IM develops in the atrophic mucosa and is believed to constitute the background in 
which dysplasia and further intestinal adenocarcinoma occurs
30
.  
Prevalence of ACG 
Generally, similar to the geographic distribution of GC incidence, consistently low ACG 
prevalence was reported from Scandinavian countries
31, 32
 (in Sweden, about 6%-8%
33, 34
), in 
contrast to much higher prevalence proportions (20%-80%) observed in Asia and South 
America
34, 35
. But inconsistent data commonly appeared even within the same population, 
since the selection of the study population and the definition of ACG can be quite different 
between studies.  
Additionally, the descriptive epidemiology of this potentially precancerous lesion with regard 
to its secular trend in the general population is less well studied, mainly due to its virtual lack 
of clinical symptoms. The few data available from Europe suggested an overall declining 
trend, without mentioning any age-specific trend
36
; whereas our previous cross-sectional 
analyses
4
 of the population-based material in Sweden during 1990-1999 revealed an 
unexpected rise in the prevalence of ACG among 35-44 year-olds. Since ACG in the long 
term is tightly associated with the GC incidence, more in-depth studies for confirming such a 
trend are highly indicated. 
Serological diagnosis 
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Clinically, ACG is diagnosed by histological assessment on gastric biopsies sampled during 
routine gastroscopy. However, as an invasive medical examination, this approach is 
practically infeasible for large-scale investigation with the objective of unveiling the 
prevalence rate among certain populations. Histology-based studies are usually limited by 
their biased sampling resources (e.g. hospital-based
37
) or small sample sizes. In contrast, 
serum pepsinogen concentration tests, which are less costly and invasive, have been widely 
accepted as a compromised choice in population-based screening surveys
38-40
. Validation 
studies
31, 41-43
 demonstrated a reasonable accuracy along with a particular high specificity 
(95%-100%) of this serology method. However, inconsistencies in definition and cut-off 
values undermine the comparability of different serology-based studies. 
2.2.3 Other possible factors that can affect the stomach microenvironment 
2.2.3.1 Long term proton pump inhibitor use 
Proton pump inhibitors (PPIs) are the most efficacious medication to reduce the secretion of 
gastric acid. Nowadays, in addition to short-term use, e.g. for eradication of H. pylori 
infection or management of gastroesophageal reflux disease, maintenance PPI therapy is also 
recommended, particularly for patients with erosive oesophagitis or/and Barret's 
oesophagus
44
. However, recently, the long-term use of this potent antisecretory medication 
has been suggested to be correlated to an altered ACG or GC risk
45
, although this association 
has not been clearly established. 
The PPI-related hypochlorhydria is the main concern for explaining the potential GC risks, 
especially for the patients with H. pylori infection. In subjects with suppressed acid secretion 
caused by maintained PPI use or any other mechanisms, H. pylori infect both the antrum and 
body of the stomach, instead of the antrum only. This unusual colonization pattern leads to 
corpus predominant gastritis
46
, which subsequently results in the accelerated appearance of 
ACG — a major risk factor for the development of GC. 
Non-Helicobacter bacterial overgrowth is another potential factor which can affect the 
development of gastric premalignant lesions under the condition of sustained low gastric acid 
level. In patients without long-term PPI use, it probably occurs after the formation of severe 
ACG. In PPI users, however, colonization of various microbes could happen at an earlier 
stage and might facilitate the further development of more severe gastritis
47
. Moreover, 
possible carcinogens produced by these microbes (e.g. nitrosamines and acetaldehyde) might 
also promote the development of precancerous lesions, or even carcinoma itself. 
2.2.3.2 Appendectomy 
The vermiform appendix is historically considered as a vestigial organ and the loss of the 
appendix is thought to have few, if any, long-term effects. Appendectomy is often performed 
after a clinical suspicion of appendicitis, because definitive test seems to be time-consuming 
and not beneficial given the low risk of appendix removal. Recent work suggests that the 
appendix may serve as a reservoir for the colonic microbiome
48
; and after biofilm-disrupting 
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events, such as use of antibiotics or gastroenteritis, the gastrointestinal microbiome initially 
emerges from the appendix. Therefore, removal of the appendix may disturb normal intestinal 
microflora, altering many aspects of human physiology including vulnerability to 
inflammation, extraction of nutrients, and ultimately playing a role in tumor formation, 
locally (colon cancer) or specifically (non-Hodgkin’s lymphoma and other GI cancers). 
A few previous studies have examined whether or not appendicitis and appendectomy are 
associated with altered risk of gastrointestinal cancers. A Swedish registry-based 
investigation has reported a significantly increased GC risk after appendectomy, although it’s 
restricted to patients appendectomized under 20 years of age, and thus not well powered to 
examine individual cancer risk by the time it was analyzed
49
. A similar study from 
Denmark
50
 also suggested an elevated GC risk. All of these findings favor the notion that 
removal of the appendix could somehow change the microenvironment of gut, including the 
stomach, which in turn, may play an important, as-yet-unknown role in the carcinogenesis at 
the site. More recently, a trial showed that uncomplicated acute appendicitis could be treated 
with antibiotics rather than appendectomy, highlighting the importance of assessing the 
effects of appendectomy
51
.  
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3 AIMS 
The overall aim of this thesis was to examine our hypothesis that the stomach 
microenvironment-related events, including H. pylori infection, AG, and the changes of 
stomach microbial composition, may play an important role in the development of GC. 
 To gain an updated insight into epidemiological changes of ACG in Sweden, and 
search for the possible underlying explanations.      
     
 
 To explore the novel serum antibodies of H. pylori, as well as their associations with 
the development of GC. 
 
 
 To accurately measure the excess incidence of GC among endoscopy patients with 
pathological diagnosis of gastric precancerous lesions. 
 
 
  To understand if other potential factors (e.g. appendectomy) could chang the stomach 
microenviroment, thereby affecting the occurrence of GC.
   11 
4 MATERIALS AND METHODS 
4.1 SUBJECTS AND STUDY DESIGN 
Study I 
Age-stratified random samples of all 35-64 year old residents of Norrbotten and Västerbotten, 
two counties located in Northern Sweden, were drawn in 1990, 1994, 1999, 2004, and 2009 
as part of MINOCA project (Multinational Monitoring of Trends and Determinants in 
Cardiovascular Disease)
52, 53
. In each year of survey, the samples were randomly selected 
(250 random samples were collected from each sex/10-year age stratum); and each selection 
round was carried out independently of the previous ones. Information about 
sociodemographic characteristics, anthropometric measures, life style factors, medical 
history, and broad dietary patterns was collected by questionnaires; and a blood sample was 
also acquired from each participant. The participation rate ranged from 69% to 81%, across 
different sampling years. Briefly, non-participants tended to be younger and mostly males, 
reported lower body mass index (BMI) and were more likely to be cigarette or snuff users 
compared to participants
54
.  
Based on the Northern Sweden MONICA project, Study I was conducted consisting of two 
parts. The first part has a cross-sectional design. From all participants aged 35-64 years, we 
drew a random sample consisting of 5284 individuals to assess the age- and calendar year-
specific prevalence of serologically defined ACG. Then, in the second part, all serologically 
identified ACG cases together with their 1:3 randomly selected controls, who were frequency 
matched with cases by age group and year of sampling, were involved in a subsequent case-
control study. Analyses were executed by combining lab results (the presence of antibodies 
against H. pylori and CagA) and questionnaire data. 
Data (n=3266) from the first three occasions (1990/1994/1999) of this project have been 
analysed in 2002, and described in details in Maria Held’s thesis4. Later, after performing 
serology tests on additional 2018 sera from the last two occasions (2004/2009), we merged 
the two datasets, and presented them together in paper I.  
Study II 
The second study is a population-based case-control study. The study base consisted of all 
native Swedish individuals between 40 and 79 years of age, living in 5 counties (distributed 
in 2 geographic areas with different incidence rates) in Sweden from February 1989 to 
January 1995
20
. Newly diagnosed patients with histologically confirmed GAC were identified 
as eligible cases; and in parallel with the case ascertainment, controls were randomly selected 
with an approximately 2:1 frequency matched to the cases by age and sex. Venous blood 
samples were required from study participants during the last few years of the study. In total, 
298 case patients (participation rate was 100%) and 244 control subjects (participation rate 
was 70.5%) with blood samples (collected preoperatively for cases) were involved in our 
study. The crucial attributes that might affect the possibility of H. pylori infection, such as 
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age, sex, socioeconomic status (SES) in childhood, education level, as well as cancer type 
and site,  were distributed equally among subjects in this serological sub-study and all 
subjects in the whole study
55
. 
Study III 
Proceeding from computerized Swedish pathology registers, we established a cohort 
consisting of all patients who had gastric biopsies taken on non-malignant indications 
between 1979 and 2011. The 24 pathology departments provided the patients’ national 
registration numbers (NRNs – unique identifiers for all Swedish residents) along with data on 
date, age, sex, and pathological-anatomical diagnosis using the Systematized NOmenclature 
of MEDicine Morphology (SNOMED M) codes.  
In total, 405,211 eligible subjects were enrolled and followed for GC occurrence until the end 
of 2011.The cohort members were grouped by their SNOMED M diagnosis at baseline (first 
biopsy identified in the database). Our main focus was on Correa’s cascade, with the groups 
(in order of progression): normal, minor mucosal changes, non-atrophic chronic gastritis, AG, 
IM and dysplasia. However, to prevent the possible effects of other clinical diagnoses on GC 
risk measurement, 66,300 patients whose main findings were of uncertain relevance to 
Correa’s cascade lesions and to GC development were firstly identified and analyzed 
separately in a subcohort named ‘other diagnoses subcohort’. For the remaining 338,911 
patients (referred to as ‘Correa’s cascade subcohort’ hereinafter) with normal gastric mucosa, 
minor changes, or lesions in Correa’s cascade, baseline grouping was determined by the 
diagnostic code that indicated the most advanced lesion. Outcome and censoring information 
was collected from essentially complete health and demographic registers. 
Study IV 
The fourth study is a population-based cohort study that was conducted on the basis of 
National Patient Registry (NPR) of Sweden. A total of 501,160 patients who received 
appendectomy during January 1, 1970 to December 31, 2009 were identified by using 
Swedish surgery codes (4510, 4511, 4517,0058 during the time period 1970–1996, and 
JEA00, JEA01, JEA10 for 1997 and onwards). After exclusion of 20,778 patients with 
conflicting information (having emigration/death date recorded before the appendectomy 
date), the final cohort consisted of 480,382 eligible subjects. The dataset was then linked to 
the Swedish Cancer Registry, where all GC cases (presenting as International Classification 
of Diseases (ICD) version 7 code=151) were ascertained. Further cross linkages with Death 
Register, Emigration Register provided the necessary information for censoring follow-up. 
 
   13 
4.2 LABORATORY METHOD 
4.2.1 Enzyme linked immunosorbent assay (ELISA) test for pepsinogen (PG) 
level 
In Study I and II, we measured serum concentration of PG I and II by using ELISA method 
according to the instructions of the manufacturer (Biohit Plc, Helsinki, Finland). The test is 
based on a sandwich enzyme immunoassay technique with a PGI/PGII specific antibody 
adsorbed on a microplate and a detection antibody labelled with horseradish peroxidase. 
When the enzyme reaction was finally terminated with stop solution, the intensity of the 
yellowish colour is directly related to the PGs concentration of the sample.  
Quality control during testing  
Whenever the test was performed, besides a positive control and a blank control provided by 
the producer, a pooling sample (produced by mixing sera donated by 5 healthy volunteers) 
was always added in duplicate in each plate to monitor the intra/inter-assay imprecision. 
Results indicated that the within-assay imprecision was consistently low (< 3%), and 
coefficient of variation (CV) for between-assay imprecision was, in Study I, 6.2% for PGI 
and 7.0% for PGII, in Study II, 7.0% for PGI and 10.8% for PGII. Additionally, to minimize 
the effect of between-assay variations on the results, samples collected from different survey 
occasions (Study I), or sera from cases and controls (Study II), were first mixed and then 
evenly placed in each plate.  All tests were conducted continuously and finished within a 
short time period. 
Cut-off points for atrophy diagnosis 
Without agreement on the best cut-off values, various definitions were applied in different 
serology-based studies
56
. In Study II, we used the cut-off points which have been validated 
in Swedish population for AG diagnosis. With the criteria that PGI <25µg/l or the ratio 
PGI/PGII<3, the sensitivity and specificity of the markers for advanced AG were 71% (CI 
68-74%) and 98% (CI 97-99%) respectively
33
.  
For Study I, however, since PG-I levels in 3266 serum samples from the first three occasions 
(1990/1994/1999) have been measured in 2002 by using a different commercial kit— 
immunoenzymometric assay (Gastroset PG-I, Orion Diagnostica, Espoo, Finland) which had 
gone out of production, we failed to use exactly the same analysis kit for all 5284 samples. 
The definition of the old kit (PG-I < 28 µg/L) offered a sensitivity of 81% and a specificity of 
99% for the presence of ACG
31
, with histology as the gold standard. Therefore, to maximize 
the consistency of these two kits, a specific cut-point (PG-I <45 µg/L) was selected for the 
new kit through comparison of the results measured by the two kits in a pilot validation study. 
4.2.2 Immunoblot for H. pylori status  
Part of the sera from Study I (for individuals recruited in the subsequent case-control 
analysis) were analysed for the presence of antibodies against H. pylori and CagA protein 
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with a commercially available immunolot assay (Helicoblot 2.1, Genelab Diagnostics, 
Singapore). The testing procedure and the result interpretation followed the instructions of the 
manufacturer. CagA was positive if 116,000-Mr band was present. H. pylori seropositivity 
was defined as presence of any of the following conditions: (i) a positive result for the 
116,000-Mr band and one or more of the 89,000-, 37,000-, 35,000-, 30,000-, and 19,500-Mr 
bands together or along with the presence of the current infection marker (CIM); (ii) the 
presence of the 89,000-, 37,000-, or 35,000-Mr band; and (iii) the presence of both the 
30,000- and 19,500-Mr bands. The sensitivity and specificity of this test for current H. pylori 
infection has been reported to be 95%-99% and 93%-98%, respectively, among American, 
Japanese and European patients
57-59
. 
4.2.3 H. pylori multiplex serology 
In Study II, by collaborating with German Cancer Research Center, we applied H. pylori 
multiplex serology test to check presence of antibodies to 17 individual H. pylori proteins 
(Table 1). This multiplex method was developed based on a glutathione-S-transferase (GST) 
capture immunosorbent assay combined with florescent bead technology
60
. The quantity of 
antibodies bound to each antigen, defined as antibody reactivity, was measured by the median 
reporter fluorescence intensity (MFI) of at least 100 beads per bead set per serum. Antigen-
specific cut-offs to determine dichotomous serostatus (positive/negative) were based on 46 
additional sera within the same assay defined as H. pylori seronegative, calculating as the 
arithmetic mean MFI plus 3 SD after excluding positive outliers. Plate-to-plate variation was 
monitored via a standard sample on each plate, revealing low flux with median CV of 10.0% 
(range 5.2% to 17.7%). All sera were tested in one assay on the same day.
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Table 2. Functions of Helicobacter pylori proteins expressed for multiplex serological test 
Protein name Full name Biological function* 
Cag A Cytotoxin associated  antigen A may be necessary for the transcription, folding, export, or function of the cytotoxin. 
GroEL Chaperonin GroEL 
 
Prevents misfolding and promotes the refolding and proper assembly of unfolded polypeptides generated 
under stress conditions. 
OMP Outer membrane protein Unknown. 
Catalase Catalase Decomposes hydrogen peroxide into water and oxygen; serves to protect cells from the toxic effects of 
hydrogen peroxide. 
VacA Vacuolating cytotoxin  Induces vacuolation of eukaryotic cells. Causes ulceration and gastric lesions. 
HcpC Helicobacter cysteine-rich protein C May hydrolyze 6-aminopenicillinic acid and 7-aminocephalosporanic acid (ACA) derivatives. 
HP0305 Hypothetical protein Unknown. 
HpaA Helicobacter pylori  adhesin A Putative neuraminyl-lactose-biding hemagglutinin homolog, which has been shown to mediate the 
binding of bacteria to sialic acid-containing host molecules expressed on the surface of gastrointestinal 
cells61. 
Cagδ Cag pathogenicity island protein 3 Protein binding; might be a novel component of CagT4S outer membrance subcomplex62. 
CagM Cag pathogenicity island protein 16 Unknown. 
HyuA Hydantoin utilization protein A Hydrolase activity 
Cad Cinnamyl alcohol dehydrongenase ELI3-2 Nucleotide binding, oxidoreductase activity, and zinc ion binding. 
HP0231 Hypothetical protein Unknown. 
NapA Nutrophil-activating protein Required for the survival in the presence of oxidative stress; also a virulence factor that activates 
neutrophils, mast cells and monocytes. It might have a role in the accumulation of neutrophils and 
monocytes at the site of infection. Induces superoxide anion generation, adhesion and chemotaxis of 
neutrophils, through a pertussis toxin-sensitive pathway involving MAP kinases. 
UreA Urease alpha subunit Ammonia produced by ureolysis increases the gastric pH thereby providing an environment permissive 
for colonization of the stomach. 
BabA Blood group antigen-binding adhesin  Devoted to the attachment to human gastric epithelium, leading to higher colonization densities and 
augmented nonspecific immune response ,and ,subsequently, more aggressive gastritis 
HomB Helicobacter outer membrane B Unknown.  
*
 The information is from Swiss-Prot database (http://www.expasy.org/sprot) except where noted otherwise. 
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4.3 STATISTICAL ANALYSES 
For case-control analyses (the second part of Study I and II), the relative importance of each 
factor was expressed as the odds ratio (OR), with two-sided 95% Wald confidence intervals 
(CIs), of having target disease (ACG /GC) among exposed relative to a reference category 
(typically, unexposed). Owing to the frequency matching design, unconditional logistic 
regression model was applied for both of these studies. Multivariate models included the 
frequency matching factors, as well as potential confounders—with biological/statistical 
importance or selected using the Akaike statistic. Potential interaction effects between 
exposures were also assessed in multiplicative model where a cross-product term represented 
the interaction between the two variables. 
In Study II, since high correlation and multicollinearity between original MFI values of the 
studied H. pylori antibodies have been noted, we didn’t add these variables directly into 
multivariate model. Instead, principal component analysis (PCA) was implemented. Briefly, 
this method is executed to supply a low-dimensional picture by viewing the correlated 
original variables (serum levels of assorted H. pylori antibodies in this case) from its most 
informative viewpoint. Original variables (MFI values of tested antibodies) were first 
restructured by B-spline transformation. Then, using the PCA method, significant 
components (or factors) were determined with eigenvalue >1.0 as the criterion. Lastly, 
stratified by quartiles of controls’ factor scores, risk levels of non-cardia GC among score-
graded subgroups were estimated by unconditional logistic regression. 
For population-based cohort study (Study III and IV), we calculated the standardized 
incidence ratio (SIR; the ratio of the observed to the expected number of newly diagnosed 
GC cases) with its 95% CIs to estimate the relative risk for each exposure group, using the 
general Swedish population as reference. The expected number of cases was calculated by 
multiplying the observed number of person-years by age- (5-year strata), sex-, and calendar 
year-specific incidence rates derived from the entire Swedish population. Particularly, a peak 
of cancer incidence was invariably observed shortly after patient enrollment. This is 
principally due to the symptomatic yet undetected cancers and closer follow-up in exposed 
cohort, reflecting possibly selection or surveillance bias. Thus, the first one (Study IV) or 
two (Study III) years of follow-up, as well as the corresponding events happening during 
that period, were disregarded from main analysis.  
In Study III, the associations between pathological changes and risk of GC were then 
evaluated by hazard ratios (HRs) with 95% CIs, derived from the Cox proportional hazards 
regression model. We used attained age as underlying time-scale, and adjusted for sex, and 
stratified by pathology units. Assumption of proportional hazards for involved variable was 
checked graphically and by the method of Schoenfeld’s partial residuals; and neither of them 
revealed indication of violation.  We also applied the Nelson-Aalen method to estimate the 
cumulative incidence of total GC among subjects with different baseline diagnoses. 
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A P value less than 0.05 was considered to be statistically significant. All statistical analyses 
were carried out using SAS 9.2-9.4 software (Cary, NC).
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5 RESULTS  
5.1 STUDY I 
5.1.1 Pilot study of consistency of results from the two PG kits 
In the pilot study, 894 sera from 900 randomly selected participants in the first three survey 
rounds, already analyzed with the old PG-I kit, were re-tested using the new kit (sera from 6 
selected participants had been used up). A strong correlation between paired measures of PG-
I concentration was noted (Pearson correlation coefficient = 0.85; Intraclass correlation 
coefficient=0.77). Plots of Bland-Altman analysis (Figure 4) revealed that the new kit could 
be of practical use, although a small upward adjustment is needed (18 units higher than the 
old kit). For sero-positivity, taking the old results as a ‘gold standard’, best agreement 
(kappa=0.80) was reached when PG-I <45 µg/L was selected as cut-off point for the new kit.  
 
Figure 4. Bland-Altman plot for comparison of pepsinogen I (PG-I) obtained in 2002 using Gastroset PG-I assay 
and PG-I measured in 2013 using PG-I ELISA Kit (n=894) 
Since serum PG II value was also suggested to be correlated with a severe, highly active 
gastritis and high incidence of gastric cancer 
63
, we evaluated PG-II levels among these sera 
using PG-II ELISA (Biohit Oy, Helsinki, Finland). However, correlation test indicated only 
moderate agreement between these two definitions (old PG-I-defined ACG vs. PG-I/PG-II-
defined atrophic gastritis, kappa=0.59). 
   19 
 
5.1.2 Prevalence of PG-I-defined functional ACG 
 
Figure 5. Observed prevalence of PG-I-defined functional atrophic corpus gastritis (ACG)* across different 
survey occasions, stratified by age group (10-year strata) 
*Defined by serum pepsinogen I (PG-I) concentration <28 µg/L (measured by Gastroset PG-I assay, Orion 
Diagnostica, Finland) for samples from 1990/1994/1999 survey occasions, and <45 µg/L (measured by PG-I 
ELISA Kit, Biohit Oy, Helsinki, Finland) for samples from 2004/2009 survey occasions. In a validation study, 
the agreement of the two kits was proved to be high (kappa=0.80). 
PG concentrations were measured in sera from 5283 subjects. One serum from 1994 was 
missing. Overall, 305 subjects (58 per 1000; 95% CI 51‒64 per 1000) were considered to be 
with significant ACG according to their PGI concentrations. Slightly higher prevalence was 
observed among women relative to men (62 versus 53 per 1000; P=0.17). Figure 5 illustrates 
the age-specific prevalence rates across the 5 sampling years. Among the entire population 
aged from 35 to 64, although having a tendency to descend, the changing trend over time was 
non-significant (the slope of the regression line indicated a prevalence reduction of -0.8 per 
1000 per year of observation; 95% CI -1.8 ‒+0.1, p=0.08). Notably, a significant fall 
appeared among 55-64 years old subjects (from 124 to 49 per 1000 between 1990 and 2009, 
corresponding to a slope of -4.0 per 1000 per year of observation; 95% CI -5.8 ‒-2.0, p 
<.0001), along with surprisingly increased prevalence rates which were continually observed 
among 35-44 year-old participants. In this subgroup, prevalence rates of ACG rose from 22 to 
64 per 1000 in last 20 years, attaining a significant trend assessed both by Mantel-Haenszel 
Chi-square test (p= 0.0073) and by the slope of the regression curve (+2.0 per 1000 per year 
of observation; 95% CI +0.5 ‒+3.5, p=0.0073). Sub-analysis confined to non-smokers 
(n=4236) revealed a very similar age-specific changing pattern (data not shown). 
5.1.3 Risk factors for the presence of PG-I-defined ACG 
In total, 305 ACG cases and 915 matched controls were included. With the exception of one 
serum which has been used up, H. pylori serology test was successfully performed on all 
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other 1219 sera. The distribution of age, sex, and other main characteristics that might affect 
ACG occurrence among cases and controls, along with their ORs estimating the relative 
probability of having ACG in various exposure strata are displayed in Table 2 (detailed 
characteristics can be found in paper I). 
Table 2 The distribution of studied factors and their associations with risk of having PG-I-defined atrophic 
corpus gastritis 
Factors    Cases /all
*
 (%)    Controls/all
*
 (%) Simply adjusted model 
OR (95% CI)
†
 
Best fitted model 
OR (95% CI)
§
 
Age group     
35-44 years 74/305 (24.3) 222/915 (24.3) - - 
45-54 years 76/305 (24.9) 228/915 (24.9) - - 
55-64 years 155/305 (50.8) 465/915 (50.8) - - 
Sex     
Female 167/305 (54.8) 453/915 (49.5) Reference Reference 
Male 138/305 (45.2) 462/915 (50.5) 0.81 (0.62-1.05) 0.75 (0.56-1.02) 
Education level     
≤12 years 254/302 (84.1) 690/908 (76.0) Reference Reference 
>12 years 48/302 (15.9) 218/908 (24.0) 0.59 (0.41-0.83) 0.62 (0.42-0.90) 
H. pylori serostatus     
Negative 145/305 (47.5) 544/914 (59.5) Reference - 
Positive 160/305 (52.5) 370/914 (40.5) 1.74 (1.31-2.29) - 
CagA serostatus     
Negative 98/305 (32.1) 451/914 (49.3) Reference Reference 
Positive 207/305 (67.9) 463/914 (50.7) 2.26 (1.69-3.02) 2.25 (1.66-3.06) 
BMI     
Normal (BMI<25 kg/m
2
) 97/305 (31.8) 391/915 (42.7) Reference 
‡ 
Overweight (BMI 25~30 kg/m
2
) 135/305 (44.3) 376/915 (41.1) 1.47 (1.09-1.99) 
‡
 
Obesity (BMI≥30 kg/m2) 73/305 (23.9) 148/915 (16.2) 2.04 (1.42-2.93) ‡ 
Diabetes     
No 285/303 (94.1) 886/910 (97.4) Reference Reference 
Yes 18/303 (5.9) 24/910 (2.6) 2.35 (1.25-4.42) 2.05 (1.05-4.00) 
Smoking status     
Never smoker 167/301 (55.5) 466/909 (51.3) Reference Reference 
Former smoker 97/301 (32.2) 270/909 (29.7) 1.00 (0.75-1.36) 1.02 (0.75-1.40) 
Current smoker 37/301 (12.3) 173/909 (19.0) 0.59 (0.40-0.88) 0.57 (0.37-0.87) 
Hard liquor  consumption     
Never 98/304 (32.2) 231/912 (25.3) Reference Reference 
A few times per year 126/304 (41.5) 432/912 (47.4) 0.68 (0.50-0.93) 0.73 (0.52-1.02) 
Once per month or more 80/304 (26.3) 249/912 (27.3) 0.75 (0.53-1.07) 0.89 (0.60-1.30) 
Fruit consumption     
Quintile1 (≤0.50 times/day) 59/305 (19.3) 202/915 (22.1) Reference - 
Quintile2 (0.51-0.98 times/day) 49/305 (16.1) 177/915 (19.3) 0.95 (0.62-1.46) - 
Quintile3 (0.99-1.50 times/day) 65/305 (21.3) 183/915 (20.0) 1.22 (0.81-1.84) - 
Quintile4 (1.51-2.22 times/day) 69/305 (22.6) 180/915 (19.7) 1.32 (0.88-1.98) - 
Quintile5 (>2.22 times/day) 63/305 (20.7) 173/915 (18.9) 1.26 (0.83-1.90) - 
*
 Total number varied due to missing information. 
†
Odds ratios and 95% confidence intervals derived from logistic regression models including the variable in 
question together with the frequency matching factors, age group (10-year strata) and survey year. 
 
§ 
Odds ratios and 95% confidence intervals derived from a best fitted logistic regression model including CagA 
serostatus, smoking status, sex, body weight, education, diabetes, and hard liquor consumption, along with the 
frequency matching factors, age group (10-year strata) and survey year. 
‡ The effects of body mass index were not shown in this table due to their significant interaction with age groups. 
These results can be found in Table 3. 
As expected, current tobacco use, but not former use, showed a negative linkage with having 
a significantly low PGI level. No such relationship was observed among current snuff users. 
Assessed by a simple logistic regression model that only adjusted for the frequency matching 
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variables, OR among H. pylori seropositive subjects, as opposed to H. pylori seronegative 
ones, was 1.7 (95% CI 1.3-2.3). A stronger, but unimpressive, association was observed 
between CagA serostatus and ACG risk (OR=2.3; 95% CI 1.7-3.0). With regard to 
sociodemographic factors, sex and county of residence seemed to be irrelevant to the 
occurrence of PGI-defined ACG, while overweight or obesity, and lower education level 
(<12 years) were significantly linked to increased odds of having this disease. The 
importance of diabetes was marked by its elevated OR, which indicated that diabetes patients 
had 2.4-fold increased odds of developing ACG, compared to the ones without a history of 
diabetes. Recent PPI use was only reported in 1.6% (19/1220) of all studied subjects. Despite 
a slightly higher prevalence among cases than controls, we observed no significant 
association of PPI use with ACG. All types of alcohol intake, notably wine and hard liquor 
consumption, exhibited a protective tendency against ACG, with ORs lower than unity. No 
apparent impact was noted regarding coffee, vegetable, and fruit intake.    
Moderate correlations were detected within four groups of variables: CagA/ H. pylori sero-
status, wine/beer/hard liquor consumption, fruit/vegetable intake, and snuff/ cigarette use. 
Therefore, in fully adjusted multivariate model, only the most significant one from each 
group was included. The best fitted model that obtained the lowest AIC included CagA 
serostatus, smoking status, sex, obesity, education, diabetes, and hard liquor consumption. 
Briefly, all tested factors acquired almost identical results from these two multivariate 
models. Compared to results derived from simply adjusted model, the association of CagA 
serostatus with ACG remained essentially unchanged after adjustments for additional 
covariates, with an OR of 2.3(95% CI 1.7-3.1). The same situation was found for education. 
After full adjustment, subjects who had more than 12 years of education had 38% lower odds 
of having PGI-defined ACG, compared with the ones having lower education level. Partly 
attenuated by the further adjustment, the association between self-reported history of diabetes 
and ACG occurrence still attained the level of significance, with point estimated OR of 2.1 
and 95% CI 1.1-4.0 in the best fitted model.  
Particularly, interaction between age groups and BMI levels on ACG was observed, 
indicating that the effect of BMI varied in different age groups (Table 3). Among participants 
aged 35-44 years, the presence of higher BMI levels entailed increasing odds for ACG—
subjects who were overweight and obese exhibited 2.8-fold (95% CI 1.5-5.4) and 4.7-fold 
(95% CI 2.1-10.5) increased odds, respectively, than the ones having lower BMI value. While 
for the two other age groups, no such relation could be conferred.  
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Table 3. Relationship of overweight/obesity with PG-I-defined functional atrophic corpus gastritis by age group 
Age group                     BMI level
*
 Cases (%) Controls (%) OR (95% CI)
†
 OR (95% CI)
§
 
35-44 years   Normal 24 (32.4) 131 (59.0) Reference Reference 
Overweight  31 (41.9) 69 (31.1) 2.84 (1.49-5.40) 2.78 (1.47-5.27) 
Obesity  19 (25.7) 22 (9.9) 4.73 (2.13-10.46) 4.59 (2.09-10.09) 
45-54 years  Normal 28 (36.8) 96 (42.1) Reference Reference 
Overweight  28 (36.8) 95 (41.7) 1.05 (0.60-1.97) 1.06 (0.57-1.97) 
Obesity  20 (26.4) 37 (16.2) 1.32 (0.63-2.79) 1.32 (0.63-2.76) 
55-64 years  Normal 45 (29.0) 164 (35.3) Reference Reference 
Overweight  76 (49.0) 212 (45.6) 1.29 (0.83-2.00) 1.27 (0.82-1.97) 
Obesity  34 (22.0) 89 (19.1) 1.28 (0.74-2.20) 1.26 (0.73-2.16) 
* 
BMI: body mass index; Normal=BMI<25 kg/m
2
; overweight=BMI 25~30 kg/m
2; obesity=BMI≥30 kg/m2. 
†
 Odds ratios and 95% confidence intervals derived from a fully adjusted logistic regression model, including 
CagA serostatus, smoking status, sex, county of residence, body weight, education, diabetes, PPI use, coffee, 
hard liquor, and fruit consumption, along with the frequency matching factors, age group (10-year strata) and 
survey year. 
§
 Odds ratio and 95% confidence intervals derived from a best fitted logistic regression model, including CagA 
serostatus, smoking status, sex, body weight, education, diabetes, and hard liquor consumption, along with the 
frequency matching factors, age group (10-year strata) and survey year 
In further confirmatory analyses, restricting to non-smokers only or using birth cohort 
clustered multilevel regression models, almost identical strength of associations were 
detected for each risk factor (data not shown). 
5.1.4 Changes in exposure prevalence 1990-2009 
Analysis of the case-control investigation indicated that similarly descending tendencies were 
observed in both case (subjects with PGI-defined ACG) and control groups (data not shown). 
Nevertheless, a tendency for converged curves revealed that the H. pylori prevalence dropped 
more sharply among 55-64 years old subjects, relative to the younger ones aged 35-44 
(Figure 6, panel A)—in the former the slope was -14.3 (95% CI -20.3 ‒ -8.2, P < 0.001) per 
1000 per year while in the latter, it was -7.2 (95% CI -14.3 – -0.1, P=0.05) per 1000 per year 
(P for difference between slopes = 0.16). The convergence of curves was more clear for the 
prevalence of CagA seropositivity (Figure 6, panel B) —in the oldest age band, the slope was 
-18.8 (95% CI -24.4 ‒ -13.2, P<0.0001) per 1000 per year, while the curve for the youngest 
category was almost flat (slope: -5.0, 95% CI -13.3 – +3.3, P=0.24) (P for difference between 
slopes = 0.006). 
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6A: The secular trends in prevalence proportions of H. pylori 
seropositivity across the 5 survey occasions 1990-2009, 
stratified by age groups 
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6B The secular trends in prevalence proportions of CagA 
seropositivity across the 5 survey occasions 1990-2009, stratified 
by age groups 
35-44 years 45-54 years 55-64 years Overall
 
The changing patterns of other risk factors were then examined among the entire studied 
population (n=5283). The prevalence of obesity experienced an obvious raise during the 
study period, from 11% (1990) to 22% (2009), among all 35-64 years olds; whilst in the 
youngest age category it almost quadrupled (5.5% to 21.1%). PPI users were only 
documented since 1999; and no considerable gradient regarding the proportion of PPI use 
was found across the following sampling years. For diabetes, the prevalence increased from 
2% to approximately 4% during the last 20 years in the studied population. This was mainly 
due to the elevated prevalence rates among 55-64 year olds (from 3% to 7%), while for 35-44 
year olds, the prevalence rate remained low, around 1% for each year of observation. Also, 
the proportion of highly educated subjects remarkably increased over years, from 16% in 
1990 to 31% in 2009. Age-stratified analysis indicated that the upward trends were 
undifferentiated between age groups: the 35-44 years old group changed from 20% to 37%, 
the 45-54 group from 16% to 32%, and the 55-64 group from 9% to 27%. 
5.2 STUDY II 
5.2.1 Evaluation of the associations between each serological H. pylori 
antibody and the presence of GAC 
The distribution of age, sex and other basic characteristics that might affect the possibility of 
H. pylori infection among 268 cases (48 of them with cardia, 220 with non-cardia GAC 
which were further classified as intestinal and diffuse subtypes according to Laurén’s 
Classification) and 222 controls are listed in Table 4.   
 
  
Figure 6. Age-specific secular trends in prevalence proportions of H. pylori and CagA seropositivity among 
subjects involved in the case-control analysis (n=1219) across the 5 survey occasions 1990-2009, determined by 
immunoblot kit 
* The trend across sampling years was examined by Mantel Haenszel chi-square test 
p*=0.05 
p*=0.24 
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Table 4. Basic characteristics of the study population 
 Cardia GAC, 
n (%) 
Non-cardia GAC, n (%) Control 
n (%) All Intestinal Diffuse 
Age at interview (years)      
  40-49 5(10.4) 12(5.5) 1(0.9) 11(13.6) 13(5.9) 
  50-59 6(12.5) 26(11.8) 9(7.9) 14(17.3) 11(5.0) 
  60-69 17(35.4) 62(28.2) 32(28.1) 24(29.6) 96(43.2) 
  70-79 20(41.7) 120(54.5) 72(63.2) 32(39.5) 102(46.0) 
Sex      
  Male 40(83.3) 136(61.8) 80(70.2) 46(56.8) 159(71.6) 
  Female 8(16.7) 84(38.2) 34(29.8) 35(43.2) 63(28.4) 
Smoking status      
  Never-user of tobacco 16(33.3) 75(34.3) 38(33.6) 27(33.3) 89(40.1) 
  Ex-user of tobacco 10(20.8) 55(25.1) 30(26.6) 21(25.9) 80(36.0) 
  Current user of tobacco 22(45.8) 89(40.6) 45(39.8) 33(40.7) 53(23.9) 
Socio-economic status      
  Unskilled manual workers 17(35.4) 125(56.8) 57(50.0) 49(60.5) 71(32.0) 
  Skilled manual workers 18(37.5) 46(20.9) 26(22.8) 17(21.0) 63(28.4) 
  Non-manual workers 9(18.8) 27(12.3) 14(12.3) 11(13.6) 62(27.9) 
  Self-employed persons 1(2.1) 9(4.1) 7(6.1) 2(2.5) 6(2.7) 
  Farmers 3(6.3) 13(5.9) 10(8.8) 2(2.5) 20(9.0) 
Level of fruit and vegetable consumption 
  Low 27(56.3) 110(50.2) 61(54.0) 36(44.4) 83(37.4) 
  Median 14(29.2) 75(34.3) 34(30.1) 32(39.5) 82(36.9) 
  High 7(14.6) 34(15.5) 18(15.9) 13(16.1) 57(25.7) 
Area of residence      
  South 32(66.7) 122(55.5) 61(53.5) 49(60.5) 122(55.0) 
  North 16(33.3) 98(44.5) 53(46.5) 32(39.5) 100(45.0) 
Number of siblings       
  1-2 12(25.0) 38(17.3) 22(17.5) 14(17.3) 66(29.7) 
  3-4 13(27.1) 49(22.3) 25(21.9) 18(22.2) 55(24.8) 
  5-6 12(25.0) 51(23.2) 24(21.1) 23(28.4) 54(24.3) 
  ≥7 11(22.9) 82(37.3) 45(39.5) 26(32.1) 47(21.2) 
Total subjects in each group 48 220 114 81 222 
Table 5 depicts the prevalence proportions of specific antibodies against 17 H. pylori proteins 
determined by multiplex serology and their associations with different subsites/subtypes of 
GAC. It was apparent that the associations were confined to non-cardia GAC, but showed no 
important difference between intestinal and diffuse types. Except for BabA and HP0305, 
adjusted ORs for non-cardia GAC were all above unity and were all significant, with the top 
four being CagA (OR=9.2; 95%CI 5.3-15.8), GroEL (OR=6.6; 95% CI 3.7-11.7), HyuA 
(OR=3.6; 95% CI 2.3-5.6), and VacA (OR=3.5; 95% CI 2.3-5.5). 
A correlation (P value <0.0001 in Pearson correlation test) was demonstrated between most 
of the 17 antibodies. Further we found moderate multicollinearity by collinearity diagnosis—
the largest condition index was 16.3 for continuous MFI values and 12.0 for dichotomous 
sero-status variables. 
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Table 5. The seroprevalence of antibodies against each of the 17 H. pylori proteins and their associations with sub-sites/ subtypes of gastric adenocarcinoma (GAC) 
* Relative risks are estimated by odds ratio (OR) and 95% confidence interval (CI), derived from unconditional logistic regression model with  adjustments for age, sex, area of residence, 
SES, use of tobacco, level of fruit and vegetable consumption, and number of siblings. Reference group was always the unexposed group (the group with negative sero-status of specific 
H. pylori protein) 
 
 
 
 All controls 
(n=222) 
All  GAC 
(n=268) 
Cardia  GAC 
(n=48) 
Non-cardia  GAC  
All (n=220) Intestinal (n=114) Diffuse (n=81) 
n % n % OR*(95%CI) n % OR*(95%CI) n % OR*(95%CI) n % OR*(95%CI) n % OR*(95%CI) 
VacA + 95 42.8 173 64.5 2.5(1.7-3.8) 18 37.5 0.8(0.5-1.5) 155 70.5 3.5(2.3-5. 5) 83 72.8 3.7(2.1-6.5) 56 69.1 3.9(2.1-7.4) 
HyuA+ 105 47.3 190 70.9 3.0(2.0-4.5) 24 50.0 1.4(0.7-2.8) 166 75.5 3.6(2.3-5.6) 84 73.7 2.9 (1.7-5.1) 60 74.1 4.0 (2.1-7.6) 
GroEL + 132 59.5 228 85.1 4.2(2.6-6.8) 30 62.5 1.2 (0.6-2.5) 198 90.0 6.6(3.7-11.7) 102 89.5 5.3(2.6-10.9) 73 90.1 9.0 (3.7-22.2) 
HcpC+ 77 34.7 130 48.5 1.8 (1.2-2.7) 20 41.6 1.5(0.7-2.9) 110 50.0 1.8 (1.2-2.8) 54 47.4 1.4 (0.9-2.4) 47 58.0 2.8 (1. 6-5.2) 
CagA + 108 48.7 215 80.2 4.6 (2.9-7.1) 19 39.6 0.7 (0.4-1.5) 196 89.1 9.2(5.3-15.8) 98 86.0 6.0 (3.2-11.4) 75 92.6 20.6(7.6-55.7) 
Omp+ 116 52.3 190 70.9 2.0 (1.3-3.0) 23 47.9 0.8 (0.4-1.6) 167 75.9 2.5(1.6-3.9) 85 74.6 2.1 (1.2-3.7) 61 75.3 2.9 (1.5-5.5) 
NapA+ 111 50.0 191 71.3 2.6 (1.7-4.0) 23 47.9 1.0(0.5-2.0) 168 76.4 3.4(2.1-5.4) 85 74.6 2.8(1.6-4.8) 61 75.3 3.7(1.9-7.0) 
HP0231+ 101 45.5 179 66.8 2.4 (1.6-3.6) 23 47.9 1.2(0.6-2.3) 156 70.9 2.9 (1. 9-4.6) 80 70.2 2.5(1.4-4.2) 55 67.9 2.9(1.6-5.3) 
HpaA+ 83 37.4 127 47.4 1.7(1.1-2.5) 21 43.8 1.4(0.7-2.8) 106 48.2 1.7 (1.1-2.6) 54 47.4 1.6(0.9-2.6) 40 49.4 1.9(1.1-3.4) 
HP0305+ 83 37.4 132 49.3 1.4(0.9-2.0) 19 39.6 1.1 (0.5-2.2) 113 51.4 1.4 (0.9-2.2) 55 48.3 1.3(0.7-2.1) 41 50.6 1.4(0.7-2.5) 
HomB+ 75 33.8 116 43.3 1.4(0.9-2.1) 16 33.3 1.1(0.5-2.2) 100 45.5 1.6(1.0-2.4) 50 43.9 1.5(0.9-2.4) 37 45.7 1.6(0.9-2.9) 
Catalase+ 62 27.9 129 48.1 2.2(1. 5-3.3) 16 33.3 1.4(0.7-2.8) 113 51.4 2.4 (1.6-3.7) 56 49.1 2.1(1.2-3.6) 41 50.6 2.6(1.4-4.7) 
UreA  + 114 51.4 180 67.2 1.9 (1.3-2.9) 28 58.3 1.3 (0.7-2.6) 152 69.1 2.1 (1.4-3.3) 77 67.5 1.8(1.0-3.0) 58 71.6 3.0(1.6-4.7) 
Cagδ+ 66 29.7 101 37.7 1.5 (1.0-2.3) 14 29.2 1.1 (0.5-2.4) 87 39.6 1.6 (1.0-2.5) 41 36.0 1.5(0.9-2.5) 37 45.7 2.3(1.3-4.2) 
BabA+ 35 15.8 58 21.6 1.5(0.9-2.5) 14 29.2 2.4(1.1-5.3) 44 20.0 1.3 (0.8-2.3) 22 19.3 1.2 (0.6-2.4) 18 22.2 1.8(0.9-3.7) 
Cad+ 58 26.1 97 36.2 1.8(1.1-2.7) 14 29.2 1.3(0.6-2. 7) 83 37.7 1.9(1.2-2.9) 45 39.5 2.0(1.2-3.5) 26 32.1 1.4 (0.8-2.7) 
CagM+ 52 23.4 76 28.4 1.5(0.9-2.3) 9 18.8 0.9(0.4-2.1) 67 30.4 1.6 (1.0-2.6) 36 31.6 2.0 (1.1-3.5) 22 27.2 1.5(0.8-3.0) 
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5.2.2 GAC risk by the number of positive H. pylori antibodies 
Subjects being seropositive for 4-9 and ≥10 proteins exhibited, respectively, 7.2-fold (95% CI 
3.5-14.9) and 13.0-fold (95% CI 6.3-26.9) higher odds than subjects with 0-3 positive 
proteins. This positive, number-dependent relationship was further aggrandized when we 
specifically focused on individuals classified as uninfected by the H. pylori IgG ELISA test. 
In this stratum, subjects with more than 10 positive antibodies were unexceptionally from GC 
case group. Among subjects classified as infected, the gradient could not be investigated due 
to zero non-cardia GAC cases in the reference group. 
5.2.3 Associations between H. pylori antibodies and non-cardia GAC 
stratified by AG status 
Based on PG tests (PGI< 25µg/l or PGI/PGII< 3), 50.0% (134/268) cases and 20.3% (45/222) 
controls were confirmed to be with serologically defined AG. Stratified analysis by different 
AG status (Table 6) revealed that the associations between H. pylori antibodies and non-
cardia GAC were substantially attenuated or even reversed in subjects with AG diagnosis; 
conversely, in the non-AG stratum, strength of most associations was enhanced.
 
Table 6. Association between different antibodies against H. pylori antigens and non-cardia gastric 
adenocarcinoma (GAC) stratified by serologically defined atrophic gastritis (AG) 
 AG Group 
(n=167,  non-cardia GAC /control=122/45) 
Non-AG  Group 
(n=275,  non-cardia GAC /control=98/177) 
NCGAC Control OR(95%CI)* NCGAC Control OR(95%CI)* 
n (%) n (%) n (%) n (%) 
VacA+ 83(68.0) 35(77.8) 0.6(0.2-1.6) 72(73.5) 60(33.9) 7.5(3.9-14.6) 
HyuA+ 89(72.9) 29(64.4) 1.4(0.6-3.2) 77(78.6) 76(42.9) 6.5(3.4-12.7) 
GroEL + 111(91.0) 39(86.7) 1.5 (0.5-5.3) 87(88.8) 93(52.5) 9.4 (4.2-21.1) 
HcpC+ 56(45.9) 25(55.6) 0.6(0.3-1.4) 54(55.1) 52(29.4) 3.1(1.7-5.6) 
CagA + 108(88.5) 35(77.8) 2.2(0.8-6.3) 88(89.8) 73(41.2) 17.3(7.6-39.7) 
Omp+ 84(68.9) 33(73.3) 0.7(0.3-1.5) 83(84.7) 83(46.9) 7.4(3.6-15.5) 
NapA+ 92(75.4) 34(75.6) 0.9(0.4-2.3) 76(77.6) 77(43.5) 5.8(3.0-11.3) 
HP0231+ 85(69.7) 30(66.7) 0.8 (0.4-2.0) 71(72.5) 71(40.1) 5.3(2.8-10.0) 
HpaA+ 59(48.4) 25(55.6) 0.7(0.3-1.6) 47(48.0) 58(32.8) 2.2(1.2-3.9) 
HP0305+ 53(43.4) 23(51.1) 0.6(0.2-1.3) 60(61.2) 60(33.9) 2.6(1.4-4.7) 
HomB+ 50(41.0) 23(51.1) 0.6(0.3-1.3) 50(51.0) 52(29.4) 2.5 (1.4-4.5) 
Catalase+ 59(48.4) 18(40.0) 1.4(0.6-3.0) 54(55.1) 44(24.9) 3.2(1.8-5.7) 
UreA  + 84(68.9) 31(68.9) 0.9 (0.4-2.2) 68(69.4) 83(46.9) 2.7 (1.5-4.9) 
Cagδ+ 43(35.3) 19(42.2) 0.7(0.3-1.6) 44(44.9) 47(26.6) 2.3(1.3-4.1) 
BabA+ 24(19.7) 8(17.8) 0.9(0.3-2.6) 20(20.4) 27(15.2) 1.5 (0.7-3.2) 
Cad+ 84(68.9) 33(73.3) 0.9 (0.4-2.0) 37(37.8) 42(23.7) 2.9(1.5-5.6) 
CagM+ 30(24.6) 14(31.1) 0.7(0.3-1.7) 37(37.8) 38(21.5) 3.4(1.8-6.5) 
* OR adjusted for age, sex, area of residence, SES, use of tobacco, level of fruit and vegetable consumption, and 
number of siblings. 
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5.2.4 Selection of significant H. pylori antibodies for non-AG subjects using 
Principal Component Analysis 
For 275 subjects without cardia GAC and AG, the MFI values of 17 H. pylori antibodies 
were integrated and analyzed using PCA method. Figure 7 illustrates a scree plot displaying 
the eigenvalues of computed components. The factor loading of each variable is also listed. 
Factor1 and 2, with eigenvalues >1.0 (6.6 and 1.5, respectively), were considered as 
acceptable components describing most of variation in the data. Along with the loading 
values annotated variables’ contribution to each factor, the two significant components could 
be summarized as: (1) A CagA-dominant factor, with reasonable high loadings (>0.7) from 
antibodies against CagA, and VacA, and Omp, and (2) a non-CagA factor that antibodies 
against NapA and Catalase loaded highly.  
 
Figure 7.  Principal component analysis of antibodies against 17 H. pylori proteins among subjects without serologically 
defined atrophic gastritis (patients with cardia GAC were excluded) 
Independent factor scores for newly-defined principal components were used in further 
regression models. The comparisons of non-cardia GAC risks (Table 7) among ordinal 
groups graded by the quartiles of controls’ factor scores indicated a dose-response manner for 
both factors—higher score levels seemed to be associated with an increased probability of 
having non-cardia GAC, with adjusted ORs (highest vs. lowest quart) 16.2 (95% CI 4.8-54.9) 
for the CagA-dominant factor, and 5.3 (95% CI 2.1-13.3) for the non-CagA factor. 
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Table 7. Comparison of non-cardia gastric adenocarcinoma risk among subgroups classified by factor scores of 
principle component analysis* 
Categories defined by Factor Scores 
(quartile) 
Noncardia GAC 
cases 
 (n=98) 
Controls 
(n=177) 
Noncardia GAC cases 
vs controls 
n % n % OR (95% CI)
†
 
Factor 1: Lowest level (< 1
st
 quartile) 6 6.1 44 24.9 Reference 
 Lower level (1
st
 -2
nd
 quartile) 5 5.1 45 25.4 1.0(0.2-4.1) 
 Higher level (2
nd
-3
rd
 quartile) 31 31.6 44 24.9 4.4(1.3-15.0) 
 Highest level (≥ 3rd quartile) 56 57.1 44 24.9 16.2(4.8-54.9) 
Factor 2: Lowest level (< 1
st
 quartile) 18 18.4 44 24.9 Reference 
 Lower level (1
st
 -2
nd
 quartile) 7 7.1 45 25.4 1.6(0.5-5.6) 
 Higher level (2
nd
-3
rd
 quartile) 24 24.5 44 24.9 2.3(0.9-6.0) 
 Highest level (≥ 3rd quartile) 49 50.0 44 24.9 5.3(2.1-13.3) 
*
 Analysis restricted to individuals without chronic atrophic gastritis. 
†
 OR adjusted for age, sex, area of residence, SES, use of tobacco, level for fruit and vegetable consumption, and 
number of siblings 
5.3 STUDY III 
5.3.1 Characteristics 
After excluding the first 2 years of follow-up, we identified 288,167 patients in the ‘Correa’s 
cascade subcohort’. They accrued 2,381,032 person-years at risk (Table 8). Correspondingly, 
in the ‘other diagnoses subcohort’, 54,130 patients remained after the 2-year lag, 
accumulating 381,603 person-years at risk. 
Table 8. Characteristics of patients enrolled in the stomach biopsy cohort, first two years of follow-up excluded 
*
 Baseline was defined as the first biopsy identified in the database. When multiple diagnoses were present, the 
most severe one was selected. 
† 
SD: standard deviation. 
§ 
Calculated after exclusion of the first two years of follow-up.   
Mucosal status 
at baseline* 
Number of 
subjects 
Age at entry, mean (yr) 
±SD† 
Sex  
(% male) 
Follow-up duration, 
mean (yr) ±SD† 
Accumulated person-
years§ 
Correa’s cascade      
  Normal  81,174 47.7±19.9 40.5% 9.7±5.7 621,359 
  Minor mucosal change  11,571 57.5±18.5 43.8% 10.2±6.6 95,437 
  Gastritis  167,521 58.3±18.2 46.5% 10.7±6.2 1,463,788 
  AG  14,285 60.3±18.5 41.3% 10.1±6.3 115,583 
  IM  11,530 66.1±14.7 47.8% 7.9±4.6 68,122 
  Dysplasia  2,086 65.5±14.9 51.3% 10.0±6.0 16,743 
  Overall 288,167 55.7±19.3 44.5% 10.3±6.1 2,381,032 
      
Other diagnoses      
  Cellular degeneration/ 
infiltration or abnormal 
karyotype 
826 60.1±18.8 50.9% 9.4±5.7 6,120 
  Reactive gastropathy 9,130 53.2±17.5 37.3% 5.9±2.9 35,699 
  Atypia 5,124 63.9±14.5 54.3% 11.4±6.8 48,254 
  Hyperplasia or 
hypertrophy 
12,392 60.9±16.5 40.8% 9.1±5.3 87,853 
  Metaplasia (not IM) 9,883 65.2±14.7 49.4% 10.3±5.7 82,399 
  Polyps 13,935 61.7±14.3 36.3% 9.3±5.5 101,289 
  Benign tumor 2,840 62.3±16.1 35.2% 9.0±5.6 19,989 
  Overall 54,130 60.9±16.1 41.8% 9.0±5.5 381,603 
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AG: atrophic gastritis; IM, intestinal metaplasia 
5.3.2 Risk assessments for different exposure groups 
Table 9 displays the distribution of GC cases across mucosal histology groups, along with 
crude incidence rates and SIRs. In the Correa’s cascade subcohort, the incidence of total GC 
in the ‘normal’ group was 19.5 × 10-5 year-1 (95% CI 16.2-23.3), which was equal to the 
expected incidence in the age-, sex- and calendar period-matched Swedish population 
(SIR=1.0). Starting from chronic non-atrophic gastritis, excess risks were observed which 
then increased monotonically with steps in Correa’s cascade. For the dysplasia group, the 
incidence of GC reached 262.8×10-5 year
-1
 (95% CI 190.9-352.8), corresponding to a 550% 
excess in relation to the matched Swedish population (SIR=6.5).  
For the other diagnoses cohort, except the ‘reactive gastropathy’ group, excess risk of GC 
was observed in all other lesion groups, with the top three being ‘atypia’ (SIR=4.2), 
‘metaplasia’ (3.1), and ‘benign tumor’ (2.7). The excess risk was mainly confined to non-
cardia GC, but patients with a diagnosis of ‘atypia’ had 2.7-fold increased incidence also for 
cardia GC (Table 9). 
Using Cox regression model, adjusted HRs were obtained for describing the association 
between gastric mucosal histology groups and the occurrence of GC, with the ‘normal’ group 
as reference. Elevated HR was linked with more severe exposure stratum. This trend was 
essentially the same as the one observed in SIR calculation. Compared to the normal group, 
significantly excess GC risks were found for minor mucosal change (HR 1.8, 95% CI 1.2-
2.5), gastritis (HR 2.6, 95% CI 2.2-3.2), AG (HR 4.5, 95% CI 3.5-5.8), IM (HR 6.2, 95% CI 
4.7-8.2), and dysplasia group (HR 10.9, 95% CI 7.7-15.4), after being adjusted for sex and 
stratified by pathology units. Similar but slightly higher HRs were observed when analysis 
was restricted to non-cardia GC only. 
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Table 9. Observed number of gastric cancers (GC), crude incidence rate per 100,000 person-years, and standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) by mucosal status at baseline  
 
Mucosal status 
at baseline* 
Cardia GC  Non-cardia GC  All GC 
Observed 
cases†, n 
Crude 
incidence 
rate§ 
SIR (95% CI) ‡  Observed 
cases†, n 
Crude 
incidence 
rate § 
SIR (95% CI) ‡  Observed 
cases†, n 
Crude 
incidence 
rate § 
SIR (95% CI) ‡ 
Correa’s cascade            
  Normal  24 3.9 1.0 (0.7-1.5)  97 15.6 1.1 (0.9-1.3)  121 19.5 1.0 (0.9-1.3) 
  Minor mucosal change  5 5.2 1.0 (0.3-2.3)  35 36.7 1.6 (1.1-2.3)  40 41.9 1.5 (1.1-2.0) 
  Gastritis  120 8.2 1.3 (1.1-1.6)  744 50.8 1.9 (1.8-2.1)  864 59.0 1.8 (1.7-1.9) 
  AG  12 10.3 1.6 (0.8-2.8)  104 90.0 3.0 (2.5-3.7)  116 100.4 2.8 (2.3-3.3) 
  IM  12 17.6 2.3 (1.2-4.0)  76 111.6 3.7 (2.9-4.6)  88 129.2 3.4 (2.7-4.2) 
  Dysplasia  5 29.9 3.8 (1.2-8.8)  39 232.9 7.1 (5.1-9.8)  44 262.8 6.5 (4.7-8.7) 
            
Other diagnoses            
  Cellular degeneration/ 
infiltration or abnormal karyotype 
0 0 - 
 
4 65.4 2.5 (0.7-6.3) 
 
4 65.4 2.0 (0.5-5.1) 
  Reactive gastropathy 1 2.8 0.8 (0.1-4.3)  3 8.4 0.7 (0.1-2.0)  4 11.2 0.7 (0.2-1.8) 
  Atypia 10 20.7 2.7 (1.3-4.9)  76 157.5 4.5 (3.6-5.7)  86 178.2 4.2 (3.3-5.2) 
  Hyperplasia or hypertrophy 7 8.0 1.4 (0.6-2.8)  45 51.2 2.1 (1.5-2.8)  52 59.2 1.9 (1.4-2.5) 
  Metaplasia (not IM) 6 7.3 1.0 (0.4-2.1)  97 117.7 3.6 (2.9-4.3)  103 125.0 3.1 (2.5-3.7) 
  Polyps 7 6.9 1.2 (0.5-2.5)  52 51.3 2.1 (1.6-2.8)  59 58.2 1.9 (1.5-2.5) 
  Benign tumor 2 10.0 1.6 (0.2-5.9)  16 80.0 3.0 (1.7-4.8)  18 90.0 2.7 (1.6-4.3) 
* Baseline was defined as the first biopsy identified in the database. When multiple diagnoses were present, the most severe one was selected. 
† The ﬁrst two years of observation and corresponding events were excluded. 
§ Per 100,000 person-years 
‡ Observed to expected number of GC cases, based on age- (5-year strata), sex-, and calendar year (5-year strata)-specific incidence data in the total Swedish population. Ninety-five percent CIs of SIRs were 
calculated by assuming that observed cancer occurrence followed a Poisson distribution. 
AG: atrophic gastritis; IM, intestinal metaplasia 
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The temporal pattern of GC occurrence by mucosal histology group (in Correa’s cascade 
subcohort) was illustrated in the Nelson-Aalen cumulative incidence plot shown in Figure 8. 
Since 2-year lag time was applied, time ‘0’ stands for day ‘730’ after the initial gastric 
biopsy. The curves separated out by group as expected right after time ‘0’, and the elevated 
incidence appears to have been rather stable throughout the follow-up period. 
 
Figure 8. Cumulative incidence of gastric cancer among patients with different baseline diagnoses 
AG, atrophic gastritis; IM, intestinal metaplasia 
*The first two years of follow-up were excluded. 
Figure 9 exhibits that, for patients with repeated endoscopy data, the SIRs were determined 
by both baseline diagnosis and subsequent histopathological evolution—SIRs increased with 
more advanced baseline mucosal lesions; and within each baseline mucosal status group, 
progression was consistently associated with a higher incidence of non-cardia GC than ‘no 
change’/ ‘regression’.  
 
Figure 9. Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs)
*
 for non-cardia gastric cancer 
in patients with multiple biopsy records (n=55,621), categorized by baseline
†
 exposure group and following 
changing pattern.  
*
 The first two years of observation and corresponding events were excluded. 
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† 
Baseline was defined as the first biopsy identified in the database. When multiple diagnoses were present, the 
most severe one was selected. 
5.4 STUDY IV 
5.4.1 Characteristics 
The main characteristics of the study population are listed in Table 10. 
Table 10. Description of appendectomies in Sweden during 1970-2009, grouped by underlying diagnoses 
 All appendectomy 
cohort 
Appendicitis subcohort* Other diagnoses 
subcohort
†
 
Number 480,382 327,496 152,886 
Age, mean± SD (years) 32.5±19.6 30.2±18.7 37.4±20.6 
Age group, n (%) 
0-19 years 
20-39 years 
40-59 years 
60 years and above 
 
157,024 (32.7) 
169823 (35.3) 
95527 (19.9) 
58008 (12.1) 
 
120,807 (36.9) 
120,488 (36.8) 
53,841 (16.4) 
32,360 (9.9) 
 
36,217 (23.7) 
49,335 (32.3) 
41,686 (27.3) 
25,648 (16.7) 
Sex, n (%) 
Men 
Women 
 
217,710 (45.3) 
262,672 (54.7) 
 
180,172 (55.0) 
147,324 (45.0) 
 
37,538 (24.6) 
115,348 (75.4) 
Calendar year of appendectomy, n 
(%) 
1970-1979 
1980-1989 
1990-1999 
2000-2009 
 
 
113,499 (23.6) 
139,977 (29.1) 
124,677 (26.0) 
102,229 (21.3) 
 
 
62,270 (19.0) 
88,966 (27.2) 
92,167 (28.1) 
84,093 (25.7) 
 
 
51229 (33.5) 
51011 (33.4) 
32510 (21.3) 
18136 (11.8) 
Duration of follow-up 
  mean± SD (years) 
 
18.6± 10.9 
 
17.5± 10.6 
 
20.8±11.2 
  n (%) 
 0-4 years 
 5-14 years 
 15-24 years 
 >=25 years 
 
66,417 (13.8) 
127,550 (26.6) 
134,484 (28.0) 
151,931 (31.6) 
 
46,989 (14.4) 
99,038 (30.2) 
92,666 (28.3) 
88,803 (26.1) 
 
19,428 (12.7) 
28,512 (18.6) 
41,818 (27.4) 
63,128 (41.3) 
 
* 
includes patients with perforated appendicitis (diagnoses coded as ICD-8:54000–54003, 54302, or  ICD-9: 
540A, 540B or ICD-10: K35.0, K35.1, K38.3) or acute non-perforated appendicitis (diagnosis codes of  ICD-8: 
54090–54208, or  ICD-9): 540X, 541, 542, or  ICD-10: K35.9, K36, K37). 
† 
includes patients with entirely negative appendectomy (patients ended up with a diagnosis of mesenterial 
adenititis or unspecific abdominal pain, and without any other surgical procedure appeared in the same 
hospitalization record), or incidental appendectomy (patients without appendicitis diagnosis but having 
additional surgical procedure performed at the same time as the appendectomy). 
5.4.2 GC risk among appendectomy patients 
SIRs together with their 95% CIs were calculated for all appendectomy patients, as well as 
subgroup patients with different medical diagnoses (appendicitis/other diagnosis), after 
excluding the first year of follow-up (Table 11). In general, no excess GC risk was observed. 
Sensitivity analyses that restricted to data during 1987-2009 revealed similar results as in the 
main analysis (with similar point estimates, yet wider CIs). 
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Table 11. Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for gastric cancers in 
appendectomy patients with different discharge diagnoses 
 All appendectomy cohort Appendicitis 
 
Other diagnoses 
 
 Observed 
cases
*
 
SIR (95% CI)
 §
 Observed 
cases
*
 
SIR (95% CI)
 §
 Observed 
cases
*
 
SIR (95% CI)
 §
 
Gastric cancer, all 
Non-cardia gastric cancer  
Cardia cancer 
831 
685 
146 
1.00 (0.93-1.07) 
0.99 (0.92-1.07) 
1.06 (0.89-1.25) 
496 
393 
    103 
1.01 (0.92-1.10) 
0.99 (0.90-1.10) 
1.10 (0.91-1.35) 
335 
292 
43 
0.98 (0.87-1.09) 
0.99 (0.88-1.11) 
0.95 (0.69-1.28) 
*The ﬁrst year of observation and corresponding events were excluded. 
§
 Observed to expected number of GC cases, based on age- (5-year strata), calendar year- (5-year strata) and sex-
specific incidence data in the total Swedish population. 95 % CIs of SIRs were calculated by assuming that 
observed cancer occurrence followed a Poisson distribution. 
In further stratified analysis by time period under surveillance (1-4 /5-14 /15-24 /≥25 years), 
appendectomy was associated with an increased cardia GC risk (SIR 1.63, 95% CI 1.12-2.31) 
within the first observation period (1-4 years). However, this excess risk quickly disappeared 
4 years after appendectomy. In long-term observation, no excess risk was noted, compared to 
the general population. 
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6 DISCUSSION 
6.1 METHODOLOGICAL CONSIDERATIONS 
6.1.1 Study design 
6.1.1.1 Case-control study 
In Study I and II, the associations between exposure and outcome were explored by using 
case-control analysis, which means the exposure statuses were assessed at the time/after the 
diagnosis of disease. Although this study design is thought to be efficient and worthwhile 
when studying a rare outcome (e.g. cancer), distortion caused by errors from retrospectively 
collected information is possible. Questionnaire data with erroneous recall may lead to 
misclassification of exposure (recall bias). Further, blood sampled after cancer diagnosis may 
not necessarily reflect the real condition before cancer onset — during disease progression, 
spontaneous disappearance of the causative H. pylori strains and/or immunologic anergy may 
occur 
64-66
, followed by an unclear serological status. Both of these conditions can invalidate 
the estimates, and thereby should be kept in mind when interpreting study results.   
The population-based design and the feasibility of modeling with potential confounding 
factors imply good internal validity for the case-control analyses. However, given the 
awareness of considerable geographical variations in GC incidence and H. pylori prevalence, 
whether or not these findings can be generalized to other relevant population should be 
further investigated in future studies. 
6.1.1.2    Cohort study 
In Study IV (a retrospective cohort), exposure assessment was timely enough since the loss 
of appendix happened just at the time point when appendectomy was performed, whereas in a 
cohort like that in Study III, there exists an ‘unobserved’ period before the capture of 
exposure status which needs caution. This means that individuals are recruited as ‘exposed’ 
or ‘unexposed’ at the time of initial diagnosis (exposure measured), instead of the time at 
onset of the condition (exposure started). Such left truncation of observation matters the most 
for the exposure groups with mild changes (i.e. gastritis group), which correspond to the 
stages naturally asymptomatic or mildly symptomatic. Considering the facts that our Study 
III was limited to patients who underwent gastroscopies with biopsies on clinical indications, 
and the left-truncation was impossible to be fully estimated or predicted by other covariates, 
the study results cannot be readily generalizable to non-patients (or healthy persons subjected 
to screening). To be precise, the effective exposure here is pathological diagnosis of the 
gastric mucosal lesion (derived from spontaneous medical visits and a biopsy performed on 
certain clinical indication), not the lesion itself. Other issues that can affect the external 
validity of a cohort study (i.e. Study III and IV) to relevant populations include the similarity 
between populations, and the comparability of clinical practices regarding the indications and 
diagnosis criteria. 
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Moreover, another challenge in cohort studies is the selection bias. This is especially true 
when the possibility of exposure diagnosis, namely the cohort entry, is related to the risk of 
the studied outcome. For instance, in Study III, the diagnosis of severe mucosal lesion might 
be due to the symptoms caused by an emerging malignant lesion (but not yet detected). Thus, 
ignoring such bias can lead to overestimation of the exposure effect. 
Study III and IV are population-based cohort studies conducted on the basis of Swedish 
health care system (i.e. the Swedish pathology register and Swedish patient register). Such 
study design, while facilitating the complete enrollment and follow-up, cannot provide all 
detailed information for specific research question which prevents us from accurate 
evaluations. For example, in Study III, since biopsies were performed merely for clinical 
intentions, conditions about concomitantly lesion or the status of H. pylori infection might not 
be fully recorded. Also, only limited personal data could be extracted from biopsy records. 
Consequently, some important confounders, such as family history of GC
67
 and 
environmental factors
68
, could not be considered during modeling. However, further 
molecular investigation capable of combining clinic data with genetic/epigenetic information 
obtained from preserved formalin-fixed and paraffin-embedded (FFPE) biopsy samples could 
be a potential solution to conquer this limitation. 
6.1.2 Possible bias 
6.1.2.1 Selection bias and surveillance bias 
Generally, selection bias occurs when the selection probabilities are influenced by exposure 
or target disease status, resulting in ‘the study population does not represent the target 
population’69. According to the different sources of selection bias, it can affect both internal 
and external validity of a study. 
The population-based case-control design with its relatively high response rates reduced the 
possibility of having selection bias in Study I and II. It was further verified by additional 
comparisons regarding the main characteristics between participants and non-participants
26, 54
, 
which revealed even distributions for most of those studied variables. 
As described above, the major concern of selection bias in these projects is for Study III, 
where the likelihood of patient enrollment might be increased by the symptoms related to the 
studied outcome (GC). Its effect can be visualized by the ‘interval based method’70 presented 
in Figure 11, which illustrates the calculated SIRs for several disjoint time intervals close to 
the time of entry (baseline biopsy). High SIRs which appeared in earlier intervals indicated 
that concentrated outcome events (GC) happened during the first 24 months of follow-up, 
especially the first 6 months. However, these extremely high SIRs actually mean nothing 
with regards to the purpose of exploring the association between studied gastric lesions and 
GC. It’s probably more due to mentioned selection bias71, rather than truly carcinomatous 
evolution. In addition, abnormally increased SIRs were also noted for other exposure strata 
(e.g. normal/minor change group) with inherently low risk of GC, which confirmed the 
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general effects of selection bias. Thus, in our main analysis of Study III, the first two years 
of observation and outcomes detected during the same period were discarded. 
 
Figure 10. The standardized incidence ratios (SIRs) of gastric cancer among biopsied patients with different 
pathological lesions in the stomach, by follow-up duration (n=338,911, using interval-based method, in which 
SIRs were calculated separately for different time intervals:<6 months, 6-<12 months, 12-<24 months, and 24-72 
months) AG: atrophic gastritis; IM, intestinal metaplasia 
It’s notable that this period with concentrated events can be found in any register-based 
retrospective cohort study where participants are identified from inpatient registers, even 
when the exposure and the outcome are notoriously irrelevant. This situation is caused by 
surveillance bias, which occurs when one group (usually the exposure group) is followed 
more closely than the other group (in the case of SIR calculation, the general population). In 
other words, the outcome gets a chance to be diagnosed more often because of initially 
unrelated medical visits, but not because it truly happens more often in this group. Ignoring 
the surveillance bias can lead to overestimation of exposure effects. Therefore, we always 
used a lag time (time interval between index hospitalization and start of follow-up) to wash 
out the effect of such bias on estimates. 
6.1.2.2 Misclassification of exposure  
The misclassification of exposure can introduce bias to a study. In practice, it can happen in 
many different ways, and thus have diverging effects on the studied association. Major 
possible misclassifications in this thesis include: 
ACG defined by serologic PG test (Study I and II) 
As mentioned in the ‘Method’ section, serologic PG test is the only pausible alternative to 
histopathological examiation for ACG diagnosis, and has been widely used in epidemiology 
studies. However, variations in definition and cut-off values brought difficulties in comparing 
results from different studies. Both the decrease of PG-I and PG-I/PG-II ratio have been 
suggested to be closely correlated with grade and extent of ACG 
72
. But PG-II and the PG-
I/PG-II ratio start to significantly change already during the non-atrophy gastritis stage 
73, 74
, 
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contrary to PG-I which is exclusively affected by atrophy occurring in the corpus. Therefore, 
the choice of specific cut-off point is a joint reflection of the severity of atrophy the study 
concerned and the preferred balance between specificity and sensitivity. Anyway, reasonable 
definition should rely on validation studies conducted applying the same testing method 
(ideally, exactly the same commercial kit) in the same (or at least similar) population. In a 
single study, the misclassification owing to serological definition should be randomly 
assigned (non-differential) in participants with different characteristics, e.g. case/control  
(Study II,), or recruited at different time points (Study I).      
 
Another drawback of PG-based diagnosis is that it could be influenced by factors that modify 
serum PG levels by other mechanisms than ACG. It has been reported that smokers have 
higher PG-I levels than non-smokers
75
, which therefore tends to underestimate the prevalence 
of PG-I-defined ACG among smokers. Nevertheless, the sensitivity analysis we have done by 
restricting to non-smokers (n=4236) confirmed the identified age-specific changing patterns.  
 
H. pylori antibodies detected by multiplex serology  (Study II) 
Previous studies aiming to measure the effects of H. pylori on GC occurrence have always 
faced with difficulties since a hypochlorhydric environment characterizes the intermediate 
state (AG) in the possible causal pathway. It leads to the disappearence of  H. pylori . 
Consequently, with sera sampled after GC diagnosis, we might underestimate the virtual 
association because along with the progression of ACG the reduction in antibody titer can be 
expected
66
.  This speculation has been further confirmed in our analysis, which showed the 
associations between non-cardia GC and most seromarkers were severely attenuated in the 
presence of serologically confirmed advanced AG. Under this condition, we chose to perform 
PCA for novel biomarker identification only among subjects with no serologically detected 
AG. Notwithstanding the missclassification of AG may exist (as disscussed above), this 
approach, to some extent, allays concerns about serious underestimation. 
 
Pathological diganosis for biopsy samples (Study III) 
In a large, nationwide cohort that heavily relied on data collected from pathological 
departments lasting over a span of 30 years, inconsistencies or changes in clinical practice, in 
terms of biopsy taking and pathological diagnosis, might influence the consistency of 
exposure assessment. Fortunately, although the inter- and intra-observer variation was 
inevitable, the practice guidelines for the standardized pathological diagnosis have been set 
up by the Swedish Society for Pathology, and didn’t experience any big changes during the 
study period. For biopsy-taking, no widespread and generally accepted guidelines existed 
during the whole study period, so the practice could differ by time. For example, in the early 
part of the study period, when gastroscopies were more commonly performed by surgeons, 
biopsies were normally taken only when visible abnormalities were seen. In a more recent 
era, when gastroscopies were done mainly by gastroenterologists, routine biopsies from the 
antrum and corpus were commonly taken also when there was no visible pathology. Given 
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that our strategy is to group according to the most severe diagnosis, the deviation caused by 
various biopsy practices (i.e. whether or not sampling from normal tissue) should be limited.  
Sampling errors, which are especially common when sampling patchy precancerous lesions 
(atrophy or IM)
76
, should be another possible source of misclassification. Inability to capture 
the stomach’s most advanced lesion leads to some overestimation of the GC incidence in 
groups classified as having less advanced lesions, accompanied by an underestimation in 
groups denoted as having more advanced lesions. However, in our analysis, the incidence of 
GC in the ‘normal’ group was equal to the unity that was expected in the matching 
population; and a change downward in Correa’s cascade indeed was followed by a lower GC 
incidence. These reassuring observations indicate that sampling error did not overwhelm our 
results. 
6.1.3 Confounding 
A confounder is a third variable that is associated with the exposure of interest and is 
potentially an independent cause of the outcome of interest. In other words, the apparent 
effect of the exposure is distorted as the effect of extraneous factors (confounders) is 
mistaken for, or mixed with, the actual exposure effect (which can be null)
77
. In our Study I 
and II, where detailed information acquired from interview and biological sample testing are 
available, we controlled for a range of potential confounding factors at analysis. In our 
register-based studies (Study III and IV), however, the lack of data on potential confounders 
is a concern. Further analysis of archived biological samples (Study III) on molecular level 
(e.g. measure smoking exposure by immunohistochemical quantitation of related DNA 
adducts) is a possible way to address this limitation. Future efforts in other study settings 
might also consider to collect additional information to accomplish more accurate 
assessment. In Study IV, the impact of suspected confounding factors was ‘visualized’ by 
additional risk assessment on its most relevant cancer type. Such as for smoking, SIR for lung 
cancer indicates no over-presented smokers in our appendectomy cohort as opposed to the 
general population (SIR 1.03, 95% CI 0.98-1.09). 
6.2 INTERPRETATION OF THE FINDINGS 
6.2.1 The temporal pattern of ACG prevalence 
In Study I, our analyses, based on population-based quinquennial cross-sectional surveys 
during 1990-2009 in two northern counties in Sweden (a low incidence country with world 
age-standardized incidence rates in men 6.3×10
-5
, women 3.2×10
-5
)
78
, revealed a surprising 
monotonic and significant upward trend in prevalence of PG-I-defined functional ACG in the 
youngest investigated age bracket (35-44 years); whilst a decline in prevalence was 
expectedly observed among people aged from 55 to 64 years. 
Contrary to our results, both a serology study from Japan, based on two cross-sectional 
measurements (1989 and 1996) in a selected population
79
, and an endoscopy-based study 
from Finland, involving consecutive series of outpatients from one single hospital in 1977, 
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1985 and 1992
80
, found suggestive evidence of a particularly marked decline of AG in the 
young age group (20-39 years). And an overall significant drop in the number of diagnoses of 
AG was reported in a nation-wide biopsy cohort conducted in the Netherlands during 1991-
2005
36
, although age-specific trends were not provided. Nevertheless, our finding was in line 
with a report based on cancer registration data from the US, showing that the incidence of 
non-cardia gastric cancer increased significantly among Whites aged 25 to 39 years
7
. With 
considerations to differences in terms of study design, time period, population, and disease 
definition, the discrepancies between these results do not necessarily invalidate one another. 
Admittedly, the ‘two-batch’ measurements conducted using different PGI kits can be an 
arguable issue as interpreting our outcomes, but the comparability of them has been well 
validated in a pilot study. Moreover, although point prevalence estimations could be very 
sensitive to the choice of cut-off points, secular trends were probably not seriously distorted 
because the deviation, if any, from the “true” value was most likely constant over time. This 
can be further demonstrated by the expected decreasing trend observed in the oldest age 
category, which could be viewed as a “negative control”. Therefore, it’s unlikely that the age-
related differences in secular trends could be explained by disparity between testing kits. 
Another notable result of our study is that in 2009 the prevalence of PG-I-defined ACG was 
30% higher in the younger group than that in the older group (64 versus 49 per 1000). This 
has never been reported previously. The interpretation might be that this is just a temporary, 
instantaneous pattern caused by the crossed age-specific trends of ACG prevalence. If this 
trend continues, we expect that the prevalence curve for the elderly should go up sharply in 
next 20 years since it has been theoretically reflected by current middle-age curve.  
With the strengths of our study, including its clear basis in the source population, the fairly 
large sample size, the richness of background information, and multiple observation points 
over a 20-year span, we have the reason to believe the observed upward trend among young 
middle-aged people in the prevalence of serologically defined ACG does exist. Assuming a 
constant increase (+2.0 per 1000 per year) and the same increasing rate with age observed 
today, a clear increasing trend of ACG among the whole population could be anticipated 
within the coming 10 years; and after 20 years, the number of ACG cases is expected to rise 
by approximately 29%. Given the importance of ACG to GC development, this finding might 
predict that the declining GC incidence curve may reach a nadir in the next 30-40 years in the 
studied population, followed by a new upward trend. 
6.2.2 GC risk assessment 
6.2.2.1 Among patients with H. pylori infection 
The heterogeneous outcomes of H. pylori infection imply that there exists a substratum with a 
risk that is considerably higher than that observed among all H. pylori infected. In Study II, 
we specifically focused on 17 potentially oncogenic biomarkers which are essentially 
antibodies against different H. pylori proteins. The highlight of this study is that we proposed 
a new approach to identify genuinely novel discriminative patterns of H .pylori antibodies. 
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First, multiplex serology test succeeds to illustrate the co-variances among those H. pylori 
proteins, which is compulsively sealed by surveys concentrating on a single protein. Then, 
PCA was applied as a means to cope with between-antibody correlations and entailing 
dependencies that complicate statistical modeling.  
On the basis of our results, we confirmed that CagA and other studied biomarkers were 
strongly associated with the occurrence of non-cardia GC. However, the associations could 
be severely attenuated in the presence of serologically-defined advanced AG, which causes 
the disappearance of H. pylori owing to low acid secretion. This corroborates previous results 
stated by others
64, 65, 81
. Furthermore, among patients without advanced AG, PCA identified 
two significant factors: (1) A CagA-dominant factor (antibodies against CagA, VacA, and 
Omp as prominent markers) appeared to be largely driven by CagA. Thus, its covarying 
antibodies could contribute essentially little to the discriminatory ability, although they might 
serve the purpose of decreasing misclassification of CagA-positive infection and thus 
strengthen the predictive ability. (2) The second constellation of antibodies, with NapA and 
Catalase as prominent markers and was theoretically independent of the CagA constellation, 
corresponded to a moderately strong increase in the odds of having non-cardia GC. Although 
this is not confirmative evidence indicating the direct oncogenic actions of NapA and 
Catalase — their coding genes may just happen to be adjacent to the truly causative gene(s) 
or the proteins may just be somehow intrinsically correlated to other more important proteins, 
further research on the possible oncogenic mechanisms of NapA/Catalase factor is warranted. 
Also, the reproducibility of this result in other populations needs further examination; and if it 
has been proved to be generalizable, it’s reasonable to believe that the overall cancer-
predictive ability of H. pylori serology might be improved by detecting individuals highly 
exposed to the NapA/Catalase factor among those with CagA-negative infection. 
Nonetheless, given the relatively small proportion of variance attributable to this factor, its 
clinical value may be limited. More studies aiming at identifying additional oncogenic 
virulence factors of H. pylori are necessary. 
6.2.2.2 Among endoscopy patients with stomach biopsy 
Our data, based on the largest nationwide stomach biopsy cohort reported so far, confirmed 
that among biopsy patients with clinical indications, the diagnosis of these studied precursors 
(gastritis, AG, IM, and dysplasia) indeed predicted a GC risk level above the general 
population average. And in line with results reported previously
82, 83
, the elevation of risk 
levels ranked in a way just as it’s described in Correa’s cascade: dysplasia patients 
experienced the highest relative risk (about 6.5-fold) of GC, followed by 3.4-fold, 2.8-fold, 
1.8-fold for IM, AG, gastritis patients, respectively. Among individuals who underwent 
endoscopy with biopsies taken but received diagnosis of normal histology, no excess risk of 
GC was observed (SIR=1.0), relative to general population. 
Despite the well-established neoplastic cascade, results from previous follow-up studies on 
absolute risks associated with having these precancerous lesions are inconsistent
30, 36, 84, 85
. 
Besides the geographic differences, interpretations for these variations can be: different study 
   41 
designs, limited sample sizes or follow-up period, and various approaches to deal with the 
concentrated GC events which were commonly observed after the first few years of cohort 
entry
82, 86
. One similar large biopsy cohort conducted in the Netherlands suggested an 
emphasis on the first year after index biopsy by stating that more than 25% patients from 
high-graded dysplasia group received their GC diagnosis within 1 year
82. In our analysis, 
since we particularly focused on long-term risks, a 2-year lag time was applied during which 
a large peak in incidence was observed. After 2 years, the peak was passed, so our current 
estimates cannot be blurred by the initially overlooked prevalent cases. The annual incidence 
of total GC was assessed to be19.5 × 10
-5
 (95% CI 16.2-23.3) for the ‘normal’ group, which 
then increased monotonically with each step in Correa’s cascade, and reached the highest 
level (262.8×10
-5
, 95% CI 190.9-352.8) for the group with ‘dysplasia’ diagnosis. These 
numbers can be approximately translated into a 20-year GC risk of 1 in 85 with gastritis, 1 in 
50 with AG, 1 in 39 with IM, and 1 in 19 with dysplasia among patients who undergo 
gastroscopies with biopsies on clinical indications. The elevated incidence was rather stable, 
and the gaps between cumulative incidence curves grew continuously throughout the whole 
follow-up period. Intriguingly, further analysis with repeated endoscopy data indicated that if 
reiterated biopsies showed a change – upward or downward along the Correa cascade – 
compared to the initial grouping, this seemed to have prognostic significance.   
In addition, our study also quantified GC risks among patients with some other gastric 
mucosal conditions. Patients with atypia diagnosis presented a notably increased GC risk 
(4.2-fold higher than general population), which was numerically beyond that for IM patients. 
This might be partly attributable to the ongoing debate on the definitions of ‘atypia’ and 
‘dysplasia’ within the field of pathology87, 88, since under microscopy, it can be a great 
challenge to distinguish atypia from dysplasia. Moreover, previous histological studies found 
that the strictly-defined atypia indeed highly co-occurred (49%-78%) with gastric cancers
89, 
90
, and thereafter concluded it as a neoplasic lesion and  renamed it as ‘pit dysplasia’. 
Consistent with prior reports, other gastric pathological conditions with potentially high 
cancer risks were benign tumor
91
, metaplasia, polyps
87, 92
 and hyperplasia
93
. Rather, for 
reactive gastropathy (an abnormality caused by chemical injury), no excess GC risk was 
noted
94
.    
6.2.2.3 Among appendectomized patients 
The possible linkage between GC risk and appendectomy has been suggested previously
49, 50
, 
with unclear explanation. Possible mechanisms proposed included low SES, which is linked 
to both high risk of appendectomy
95
 and H. pylori infection during childhood
96
. Moreover, 
although no evidence indicated that H. pylori infection could directly affect the pathogenesis 
of appendicitis
97
, the unspecific abdominal pain caused by H. pylori
98
 might potentially 
increase the likelihood of  having appendectomy. In addition, the so-called ‘safe house’ 
theory 
99,100
 indicated that removal of the appendix might disturb normal gastrointestinal 
microflora
101
, which in turn might have an effect on the carcinogenesis in the stomach. 
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However, physiologically, there is no clue showing that such micro-environmental dysbiosis, 
mainly occurs in the large intestine, could induce subsequent changes in foregut microbiota.  
Contrary to previous findings, our register-based cohort study (the largest one reported so 
far), found no evidence to support the supposition that the appendectomies, performed for 
either appendicitis or other indications, could alter the risk of GC occurrence. It’s notable that 
our analysis, essentially an extension of Cope’s research49, with longer follow-up period and 
without age restriction, overturned the result in the previous report. With the consideration 
that the oldest participants in Cope’s study were only 48 years old at the time of analysis, the 
limited GC cases (n=8) identified there could be driven by extreme etiology (e.g. genetic 
reason) rather than the exposure of interest. Alternatively, it’s possible that the elevated SIR 
for GC was just a chance finding. When we limited our analysis to participants aged below 
20, no such excess risk of GC could be seen anymore (data not shown). On the other hand, 
the marginally significant excess risk of GC in the study from Denmark
50
  didn’t exist among 
patients with more than 10 years of follow-up. This contradicts with the long precancerous 
period required for GC development when it’s triggered by environmental factors102, and 
therefore substantially undermines the possibility of causal relationship between 
appendectomy and GC. 
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7 CONCLUSIONS 
 The observed increasing prevalence of ACG among 35-44 years Swedes, together 
with other emerging evidence, predict that the declining GC incidence curve may 
reach a nadir in the next 30-40 years in the studied population, followed by a new 
upward trend. 
 
 Although CagA remains the strongest risk indicator,  there are other serum antibodies 
against H. pylori proteins associated with noncardia GAC risk. With principal 
component analysis, we unveiled two essentially independent constellations of 
antibodies (the CagA-dominated cluster and a novel cluster with NapA and Catalase 
as prominent markers) that both predicted risk for noncardia GAC. The addition of 
CagA co-varying seromarkers may decrease exposure misclassification of CagA-
positive infection; and detection for NapA/Catalase factor among those with CagA-
negative infection may further improve the overall cancer-predictive ability of H. 
pylori serology. 
 
 Among endoscopy patients with biopsies on clinical indications, approximately 1 in 
256 with normal mucosa, 1 in 85 with gastritis, 1 in 50 with AG, 1 in 39 with IM, and 
1 in 19 with dysplasia will develop GC within 20 years. The elevated GC incidence 
among precursor patients is stable throughout the follow-up period; and the observed 
changes during re-evaluation(s) indeed have prognostic implications.   
 
 Previous evidence regarding the association between appendectomy and GC is only 
suggestive. Based on our large nationwide cohort with a fairly long follow-up period, 
we concluded that no excess GC risk could be observed among patients who 
underwent appendectomy. 
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8 FURTURE STUDIES 
Despite that we have put a lot of efforts into attempting to improve GC risk prediction, there 
still remain many challenges. For instance, we aimed to explore the H. pylori antibodies and 
their associations with GC occurrence. However, it has been reported
64-66
 that the disease 
progression, notably severe AG, changes the conditions in the H. pylori habitat to the extent 
that the causative strains may disappear or get displaced by other more adapted strains. 
Hence, with current case-control study design with blood samples collected after cancer 
diagnosis, we cannot rule out the possibility that our findings might be affected by disease-
related changes. Fortunately, emerging new techniques might provide the possibility of 
analyzing genetic profile of the microbe by using old FFPE samples
103-105
. This new 
approach, along with our nationwide stomach biopsy cohort (introduced in Study III) where 
long-term archived samples have been collected many years ahead of GC diagnosis, offers a 
unique opportunity to expand current knowledge about carcinogenicity-driving specificities 
of colonizing H. pylori strains, as well as the role of microbe-environment interactions. Our 
future studies, therefore, will include the exploration of the relationship between H. pylori 
genetic profile (detected among biopsy patients with gastritis changes) and development of 
GC (diagnosed at least 10 years after initial biopsy) by using a nested case-control design.  
The fact that H. pylori colonize the atrophic stomach poorly, and in intestinal metaplasia 
hardly at all
106
, leads to a hypothesis that some other bacteria may be attributable to the 
development of GC. However, so far there is no longitudinal analysis exploring the 
association between the microbial ecology in atrophic mucosa and the risk of GC. Therefore, 
based on our stomach biopsy cohort, we plan to conduct a nested case-control study on 
human stomach microbiota in mucosa and GC risk among subjects with moderate to severe 
AG. 
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